Title: Evidence of Leaky Protection Following COVID-19 Vaccination and SARS-CoV-2 Infection in an Incarcerated Population

Author List: Margaret L Lind¹, Murilo Dorion¹, Amy J Houde², Mary Lansing², Sarah Lapidus¹, Russell Thomas¹, Inci Yildirim^{1,3}, Saad B. Omer^{1,4,5}, Wade L. Schulz^{6,7}, Jason R. Andrews⁸, Matt DT Hitchings⁹, Byron S. Kennedy², Robert P. Richeson², Derek AT Cummings^{10,11}*, Albert I $Kn^{1,12*}$

Affiliations:

- 1. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
- 2. Connecticut Department of Correction, Wethersfield, CT, USA
- 3. Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA
- 4. Yale Institute for Global Health, Yale School of Public Health, New Haven, CT, USA
- 5. UT Southwestern, School of Public Health, Dallas, TX, USA
- 6. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
- 7. Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA
- 8. Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA,USA
- 9. Department of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA
- 10. Department of Biology, University of Florida, Gainesville, FL, USA
- 11. Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA
- 12. Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brazil

Corresponding Authors:

Margaret L Lind, PhD Margaret.Lind@yale.edu Department of Epidemiology of Microbial Diseases Yale School of Public Health 60 College St., New Haven, CT 06510

Albert I Ko, MD Albert.Ko@yale.edu Department of Epidemiology of Microbial Diseases Yale School of Public Health 60 College St., New Haven, CT 06510

1 **Abstract:**

- $rac{2}{3}$
- 3 Whether SARS-CoV-2 infection and COVID-19 vaccines confer exposure-dependent ("leaky")
4 protection against infection remains unknown. We examined the effect of prior infection.
- 4 protection against infection remains unknown. We examined the effect of prior infection,
5 vaccination, and hybrid immunity on infection risk among residents of Connecticut correc
- 5 vaccination, and hybrid immunity on infection risk among residents of Connecticut correctional
- 6 facilities during periods of predominant Omicron and Delta transmission. Residents with cell,
- 7 cellblock, and no documented exposure to SARS-CoV-2 infected residents were matched by
- 8 facility and date. During the Omicron period, prior infection, vaccination, and hybrid immunity
- 9 reduced the infection risk of residents without a documented exposure (HR: 0.36 [0.25-0.54];
- 10 0.57 [0.42-0.78]; 0.24 [0.15-0.39]; respectively) and with cellblock exposures (0.61 [0.49-0.75];
11 0.69 [0.58-0.83]: 0.41 [0.31-0.55]: respectively) but not with cell exposures (0.89 [0.58-1.35]:
- 11 0.69 [0.58-0.83]; 0.41 [0.31-0.55]; respectively) but not with cell exposures (0.89 [0.58-1.35];
12 0.96 [0.64-1.46]; 0.80 [0.46-1.39]; respectively). Associations were similar during the Delta
- 12 0.96 [0.64-1.46]; 0.80 [0.46-1.39]; respectively). Associations were similar during the Delta
13 period and when analyses were restricted to tested residents. Although associations may n
- period and when analyses were restricted to tested residents. Although associations may not
- 14 have been thoroughly adjusted due to dataset limitations, the findings suggest that prior
- 15 infection and vaccination may be leaky, highlighting the potential benefits of pairing vaccination
- 16 with non-pharmaceutical interventions in crowded settings.
- 17

18 **Introduction**

19 A fundamental question regarding SARS-CoV-2 immunity is whether infection and 20 vaccination confer all-or-nothing or exposure-dependent ("leaky") protection against infection.
21 Despite continued evidence that prior SARS-CoV-2 infections and COVID-19 vaccines provide 21 Despite continued evidence that prior SARS-CoV-2 infections and COVID-19 vaccines provide
22 protection against infection and COVID-19 related illness, protection is incomplete.¹⁻⁸ While kev protection against infection and COVID-19 related illness, protection is incomplete.^{1–8} While key 23 reasons for imperfect protection include waning protection and variant-specific immune evasion,
24 differences in the viral dose during an infectious exposure may also contribute.^{6,9–16} In alignment differences in the viral dose during an infectious exposure may also contribute.^{6,9–16} In alignment 25 with this hypothesis, the immunity conferred by prior SARS-CoV-2 infection and COVID-19 26 vaccination have been speculated to be "leaky", whereby protection reduces infection risk on a
27 per-exposure basis.^{17–20} While there are examples of leaky vaccines for infectious diseases. 27 per-exposure basis.^{17–20} While there are examples of leaky vaccines for infectious diseases,
28 including the RTS, S/ASO1 vaccine for malaria^{20,21} and attenuated vaccines for Marek's 28 including the RTS, S/ASO1 vaccine for malaria^{20,21} and attenuated vaccines for Marek's disease,²² empirical evidence for this phenomenon has not been reported for prior SAR 29 disease, 22 empirical evidence for this phenomenon has not been reported for prior SARS-CoV-2
30 infection and COVID-19 vaccines. infection and COVID-19 vaccines.

31

32 The key barrier to interrogating leaky protection in SARS-CoV-2 immunity is the inherent 33 challenge of measuring viral dose, whether incident or cumulative over time. Investigations thus
34 rely on evaluating proxies such as proximity and duration of exposure to an infected index case. 34 rely on evaluating proxies such as proximity and duration of exposure to an infected index case.
35 Yet, the use of such proxies has been limited by the lack of reliable information at required 35 Yet, the use of such proxies has been limited by the lack of reliable information at required
36 scales and by misclassification due to movement and social interactions in real world settin scales and by misclassification due to movement and social interactions in real world settings.

 $\frac{37}{38}$ The controlled social structure of correctional facilities provides an opportunity to address 39 these limitations and delineate whether prior SARS-CoV-2 infection and COVID-19 vaccination 40 confer leaky protection. As a result of the defined housing of residents, residents can be 41 classified as having close exposures (within cell), moderate exposures (within cellblock), or no 42 documented exposures to a SARS-CoV-2 infected resident on a given day. These exposure
43 categories can serve as a proxy for exposure risk in a high transmission setting where 43 categories can serve as a proxy for exposure risk in a high transmission setting where
44 movement is restricted between spatial units. Herein, we leveraged the ability to classit movement is restricted between spatial units. Herein, we leveraged the ability to classify 45 residents by recent SARS-CoV-2 exposures and the high frequency of testing performed by the 46 Connecticut Department of Correction (DOC) to compare the risk of infection and effects of prior 47 infection, vaccination, and hybrid immunity (prior infection and vaccination) among residents 48 with cell, cellblock, and no documented exposures to SARS-CoV-2 infected residents during the 49 periods of Delta and Omicron predominance in Connecticut. USA. periods of Delta and Omicron predominance in Connecticut, USA.

 $\frac{50}{51}$

51 **Results** 52

53 *COVID-19 prevention and SARS-CoV-2 infections in the correctional system* The Connecticut DOC system is comprised of 13 facilities with a daily census of 55 approximately 9,300 residents.²³ During the study (June 15, 2021 and May, 10, 2022), a total of 56 15,444 people spent at least one night housed in a DOC-operated facility, of which, 13,490 and
57 11,492 were residents during periods, respectively, of predominant Delta variant (June 15 to 57 11,492 were residents during periods, respectively, of predominant Delta variant (June 15 to
58 December 12, 2021) and Omicron variant (December 13, 2021 to May 10, 2022) transmissio 58 December 12, 2021) and Omicron variant (December 13, 2021 to May 10, 2022) transmission in
59 Connecticut.²⁴ As of the end of the study. 48% of currently incarcerated residents had Connecticut.²⁴ As of the end of the study, 48% of currently incarcerated residents had 60 completed their primary vaccine series and 27% had received a booster dose (Figure 1.A). 61

The DOC implemented a SARS-CoV-2 testing program consisting of testing of residents who were symptomatic, were contacts of confirmed cases, were due in court or had employment required testing, and residents who were newly incarcerated or transferred between facilities (rapid antigen testing). In addition, the DOC conducted voluntary, bi-weekly mass screening of 10% of residents (RT-PCR testing). Contact tracing included testing residents of (1) the same cell as an infected resident or (2) the same cellblock or facility as an 68 infected resident if close contact (being within six feet for ≥15 minutes within a 24-hour period)

69 was reported by the infected resident (see Supplement DOC COVID-19 Testing). In total,
70 87,884 SARS-CoV-2 tests were performed during the study period, of which 20,794 were 87,884 SARS-CoV-2 tests were performed during the study period, of which 20,794 were RT-71 PCRs and 67,090 were rapid antigen tests (Figure 1.B). Contact tracing among residents
72 without reported symptoms comprised the largest proportion of testing (54%) followed by 72 without reported symptoms comprised the largest proportion of testing (54%) followed by mass
73 screening (24%; Figure 1.B). On average, the DOC tested 25% of residents every two weeks 73 screening (24%; Figure 1.B). On average, the DOC tested 25% of residents every two weeks 74 and 65% every three months during the study period.

75

76 Testing intensified from November 2021 to February 2022 (Figure 1.B) when Delta and 77 Omicron BA.1 variant transmission contributed to an epidemic wave in Connecticut. During this
78 period, the average proportion of residents tested in a 14-day period was 33.6% (red line. 78 period, the average proportion of residents tested in a 14-day period was 33.6% (red line, 79 Figure 1.C). A total of 5.079 SARS-CoV-2 infections were identified, of which 1.598 and 3. 79 Figure 1.C). A total of 5,079 SARS-CoV-2 infections were identified, of which 1,598 and 3,481 80 occurred during the Delta and Omicron periods, respectively. Among the 5,079 infections, 57%
81 and 38% were identified through contact tracing among residents without reported symptoms 81 and 38% were identified through contact tracing among residents without reported symptoms 82 and testing in the presence of recorded symptoms, respectively (Figure 1.D). and testing in the presence of recorded symptoms, respectively (Figure 1.D).

83

84 *Rolling matched cohort of residents exposed to SARS-CoV-2 infection*

We conducted a rolling matched cohort study that compared the risk of SARS-CoV-2 86 infection and effectiveness of prior infection, vaccination, and hybrid immunity among residents
87 with cell, cellblock, and without documented exposures to an infected case (Supplement Figure 87 with cell, cellblock, and without documented exposures to an infected case (Supplement Figure 88 1). A cell exposure event was defined as having ≥1 cellmate test positive for SARS-CoV-2 in the 88 1). A cell exposure event was defined as having ≥1 cellmate test positive for SARS-CoV-2 in the 89 absence of cellmates testing positive in the prior 14 days. A cellblock exposure event was absence of cellmates testing positive in the prior 14 days. A cellblock exposure event was 90 defined as having ≥1 resident of the same cellblock (but different cell) test positive in the absence of a cellmate or resident of the cellblock testing positive in the prior 14 days. Eve 91 absence of a cellmate or resident of the cellblock testing positive in the prior 14 days. Events
92 without documented exposures were defined as days when residents did not have a cell or 92 without documented exposures were defined as days when residents did not have a cell or
93 cellblock exposure event in the prior 14 days. We prevented the inclusion of multiple events 93 cellblock exposure event in the prior 14 days. We prevented the inclusion of multiple events
94 without documented exposures from the same person during a 14-day period through rando 94 without documented exposures from the same person during a 14-day period through random
95 selection. We selected a cohort of events by cluster matching on facility and calendar day and selection. We selected a cohort of events by cluster matching on facility and calendar day and 96 ascertained infection in the subsequent 14-day period during Delta and Omicron periods.

97
98 98 During the Delta period, we identified 290 cell and 5,805 cellblock exposure events
99 among the 7,389 residents who were incarcerated for \geq 14 days and spent \geq 1 night in a cell 99 among the 7,389 residents who were incarcerated for ≥14 days and spent ≥1 night in a cell with 100 a roommate (Figure 2.A). Among the 584,629 events without documented exposures, we 100 a roommate (Figure 2.A). Among the 584,629 events without documented exposures, we
101 andomly selected 37,394 unique events. After matching, we identified a sample of 264 ce 101 randomly selected 37,394 unique events. After matching, we identified a sample of 264 cell
102 exposure events (258 residents), 5,616 cellblock exposure events (3,745 residents), and 17 102 exposure events (258 residents), 5,616 cellblock exposure events (3,745 residents), and 17,024
103 events without documented exposure (6,073 residents). events without documented exposure (6,073 residents).

104

105 During the Omicron period, we identified 796 cell and 6,408 cellblock exposure events 106 and 259,320 events without documented exposures among 6,161 residents who were 107 incarcerated for \geq 14 days and resided in a cell with a roommate for \geq 1 day (Figure 2.B) 107 incarcerated for ≥14 days and resided in a cell with a roommate for ≥1 day (Figure 2.B). We randomly selected 20,125 of 259,320 events without a documented exposure. Following 108 randomly selected 20,125 of 259,320 events without a documented exposure. Following
109 matching, we selected 702 cell exposure events (671 residents), 5,980 cellblock exposure 109 matching, we selected 702 cell exposure events (671 residents), 5,980 cellblock exposure
110 events (4,135 residents), and 13,464 events without documented exposures (5,429 resider events (4,135 residents), and 13,464 events without documented exposures (5,429 residents).

 $\frac{111}{112}$

112 *Characteristics of residents with and without exposure to SARS-CoV-2 infections*

113 During the Delta period, events with and without documented exposures occurred 114 among racially similar residents and residents with similar cell sizes (median: 2 residents). 115 However, cellblock exposure events occurred more frequently among residents of larger median 116 cellblock sizes (107.0 residents) than cell exposure events (73.5 residents) or events without 117 documented exposures (88.0 residents). Cell exposure events occurred more frequently amo 117 documented exposures (88.0 residents). Cell exposure events occurred more frequently among
118 unvaccinated residents (58.7%) than cellblock exposure events or events without a documented unvaccinated residents (58.7%) than cellblock exposure events or events without a documented 119 exposure (46.3%). Cell exposure events occurred less frequently among people with recorded

120 prior infections (32.2%), vaccination (41.3%), or hybrid immunity (17.1%) than events without 121 documented exposures (infection, 38.8%; vaccination, 53.7%; hybrid, 25.2%; Table 1). Male 121 documented exposures (infection, 38.8%; vaccination, 53.7%; hybrid, 25.2%; Table 1). Male 122 residents were more likely to have had a prior, recorded SARS-CoV-2 infection than female
123 residents regardless of their SARS-CoV-2 exposure status (Supplement Table 1). Among 123 residents regardless of their SARS-CoV-2 exposure status (Supplement Table 1). Among
124 residents of the same age, race, room-size, cellblock, and inclusion time, the time since la residents of the same age, race, room-size, cellblock, and inclusion time, the time since last 125 prior infection and vaccination did not differ significantly between residents with and without 126 documented exposures (Supplement Table 2).

 $\frac{127}{128}$

128 During the Omicron period, events with and without documented exposures occurred
129 among racially similar residents and residents with similar cell and cellblock sizes. Cell expos 129 among racially similar residents and residents with similar cell and cellblock sizes. Cell exposure
130 events occurred with similar frequency among unvaccinated residents (46.0%) as cellblock 130 events occurred with similar frequency among unvaccinated residents (46.0%) as cellblock
131 exposure events (43.1%) and events without documented exposures (42.9%). Cell exposure 131 exposure events (43.1%) and events without documented exposures (42.9%). Cell exposure
132 events occurred less frequently among people with recorded prior infections (36.2%) or hybric events occurred less frequently among people with recorded prior infections (36.2%) or hybrid
133 immunity (23.9%) than cellblock exposure events (prior infection: 43.6%; hybrid immunity: immunity (23.9%) than cellblock exposure events (prior infection: 43.6%; hybrid immunity: 134 28.9%) or events without documented exposures (prior infection: 47.0%; hybrid immunity: 135 30.4%; Table 1). Male residents were more likely to have had a prior, recorded SARS-CoV-2
136 infection than female residents regardless of their exposure status (Supplement Table 1). 136 infection than female residents regardless of their exposure status (Supplement Table 1).
137 Among residents of the same age, race, room-size, cellblock, and inclusion time, the time 137 Among residents of the same age, race, room-size, cellblock, and inclusion time, the time since
138 last prior infection and vaccination did not differ significantly between residents with and without 138 last prior infection and vaccination did not differ significantly between residents with and without 139 documented exposures (Supplement Table 2).

- documented exposures (Supplement Table 2).
- 140

141 *High exposure settings in cells and cellblocks impart increased infection risk*

142 During the Delta period, 122 residents tested positive following an event without
143 documented exposure, 233 residents tested positive following a cellblock exposure ever 143 documented exposure, 233 residents tested positive following a cellblock exposure event, and 144 53 residents tested positive following a cell exposure event (Figure 2.A). The hazard of infection was 2.67 (95% Confidence Interval [CI]: 1.84-3.88) and 9.70 (6.29-14.96) times higher following
146 cellblock and cell exposure events than events without documented exposure, respectively 146 cellblock and cell exposure events than events without documented exposure, respectively 147 (Figure 3). The hazard of symptomatic infection, defined as a positive rapid antigen test 148 collected from a symptomatic resident, was 2.21 (1.28-3.82) and 7.44 (3.87-14.30) times higher
149 following cellblock and cell exposure events than events without documented exposure, following cellblock and cell exposure events than events without documented exposure, 150 respectively (Supplement Figure 2; Unadjusted estimates: Supplement Table 4).

151
152 152 We conducted a series of sensitivity analyses to address concerns regarding potential
153 sources of bias (Supplement: Sensitivity Analyses). Of primary concern is the bias resulting 153 sources of bias (Supplement: Sensitivity Analyses). Of primary concern is the bias resulting
154 from inequal testing following events with and without documented exposure (Figure 1.C: from inequal testing following events with and without documented exposure (Figure 1.C; 155 Supplement Figure 4). To examine these biases, we performed sensitivity analyses (1) 156 restricted to residents who were tested during follow-up and (2) restricted to residents tested 157 during follow-up for non-symptomatic reasons. Following the restriction to tested residents, the
158 hazard of infection was 1.89 (1.36-2.64) and 5.23 (3.50-7.82) times higher following cellblock 158 hazard of infection was 1.89 (1.36-2.64) and 5.23 (3.50-7.82) times higher following cellblock
159 and cell exposure events than events without documented exposures, respectively (Suppleme 159 and cell exposure events than events without documented exposures, respectively (Supplement 160 Figure 5: Unadiusted estimates: Supplement Table 9). Restricting to tests conducted for non-160 Figure 5; Unadjusted estimates: Supplement Table 9). Restricting to tests conducted for non-161 symptomatic reasons resulted in the exclusion of an additional 12 facility exposure events and 162 the point estimates were within 0.01 of the sensitivity analysis restricting to tested residents 163 (Supplement Figure 7; Unadjusted estimates: Supplement Table 11).

164

Additionally, we did not have access to community infection data and were concerned about the bias introduced from prior infection misclassification. To reduce this bias, we 167 conducted a sensitivity analysis limited to people incarcerated since the beginning of our study
168 (June 15, 2021). The hazard of infection was 3.15 (2.01-4.92) and 12.96 (7.90-21.26) times (June 15, 2021). The hazard of infection was 3.15 (2.01-4.92) and 12.96 (7.90-21.26) times higher following cellblock and cell exposure events than events without documented exposure, respectively (Supplement Figure 9; Unadjusted estimates: Supplement Table 13). Further, since

171 we may have overestimated the effect of facility exposures by including residents who were
172 exposed to more than one index case on a given day, we conducted a sensitivity analysis exposed to more than one index case on a given day, we conducted a sensitivity analysis 173 limited to cellblock and cell exposure events with only one index case. To ensure including
174 already infected residents did not drive our findings, we conducted an analysis restricted to 174 already infected residents did not drive our findings, we conducted an analysis restricted to
175 residents who tested negative in the prior five days. To ensure our exposures were tempora residents who tested negative in the prior five days. To ensure our exposures were temporally 176 linked to observed infections, we conducted two sensitivity analyses: one excluding the first 2
177 days of follow-up, and one limiting follow-up to nine days. We found that cellblock and cell days of follow-up, and one limiting follow-up to nine days. We found that cellblock and cell 178 exposure events were significantly associated with the hazards of infection for each scenario
179 (Supplement Figures: 11, 13, 14, 16; Unadjusted estimates: Supplement Table 15, 17, 18, 20 (Supplement Figures: 11, 13, 14, 16; Unadjusted estimates: Supplement Table 15, 17, 18, 20). 180
181

181 During the Omicron period, 167 residents tested positive following an event without 182 documented exposures, 502 residents tested positive following a cellblock exposure event, 182 documented exposures, 502 residents tested positive following a cellblock exposure event, and
183 109 residents tested positive following a cell exposure event (Figure 2.B). The hazard of 183 109 residents tested positive following a cell exposure event (Figure 2.B). The hazard of 184 infection was 3.34 (2.22-5.00) and 4.73 (3.05-7.36) times higher following cellblock or cell infection was 3.34 (2.22-5.00) and 4.73 (3.05-7.36) times higher following cellblock or cell 185 exposure events than events without documented exposure, respectively (Figure 3). The hazard 186 of symptomatic infection was 3.82 (2.08-7.00) and 7.00 (3.61-13.58) times higher following
187 cellblock and cell exposure events than events without documented exposure, respectively cellblock and cell exposure events than events without documented exposure, respectively 188 (Supplement Figure 2; Unadjusted estimates: Supplement Table 4).

189
190 190 We conducted the same sensitivity analyses as for the Delta period. Following the
191 restriction to tested residents, the hazard of infection was 2.14 (1.62-2.82) and 2.23 (1.62-191 restriction to tested residents, the hazard of infection was 2.14 (1.62-2.82) and 2.23 (1.62-3.07) 192 times higher following cellblock and cell exposure events than events without documented 193 exposure, respectively (Supplement Figure 5; Unadjusted estimates: Supplement Table 9).
194 Following the restriction to residents incarcerated since the beginning of the study, the haza 194 Following the restriction to residents incarcerated since the beginning of the study, the hazard of 195 infection was 4.40 (2.84-6.82) and 6.17 (3.75-10.14) times higher following cellblock and cell 195 infection was 4.40 (2.84-6.82) and 6.17 (3.75-10.14) times higher following cellblock and cell 196 exposure events than events without documented exposure (Supplement Figure 9; Unadjusted estimates: Supplement Table 13). Cellblock and cell exposures were found to be significantly estimates: Supplement Table 13). Cellblock and cell exposures were found to be significantly 198 associated with an increased hazard of infection for each additional scenario (Supplement 199 Figures: 7, 11, 13, 14, 16: Unadiusted estimates: Supplement Tables 11, 15, 17, 18, 20). 199 Figures: 7, 11, 13, 14, 16; Unadjusted estimates: Supplement Tables 11, 15, 17, 18, 20).

 $\frac{200}{201}$

201 *High exposure setting overcomes the protection afforded by infection, vaccination, and* 202 *hybrid immunity*

203 During the Delta period, the effectiveness of prior infection at reducing the hazard of 204 SARS-CoV-2 infection was highest following events without documented exposure (Hazard 204 SARS-CoV-2 infection was highest following events without documented exposure (Hazard 205 Ratio [HR]: 0.21 [0.11-0.39]) and lowest following cell exposure events (HR: 0.59 [0.30-1.16] Ratio [HR]: 0.21 [0.11-0.39]) and lowest following cell exposure events (HR: 0.59 [0.30-1.16]). 206 Vaccine effectiveness was highest following events without documented exposure (HR: 0.32 207 [0.21-0.49]) and lowest following cell exposure events (HR: 0.74 [0.37-1.48]). The effectiveness 208 of hybrid immunity was highest following events without documented exposure (HR: 0.05 [0.02-
209 0.10]) and lowest following cell exposure events (HR: 0.29 [0.07-1.12]). The effectiveness of 209 0.10]) and lowest following cell exposure events (HR: 0.29 [0.07-1.12]). The effectiveness of 210 prior infection, vaccination, and hybrid immunity was significantly lower following cell exposur 210 prior infection, vaccination, and hybrid immunity was significantly lower following cell exposure
211 events than following events without documented exposure (P=0.029, 0.033, 0.026, events than following events without documented exposure $(P=0.029, 0.033, 0.026,$ 212 respectively; Figure 4/Supplement Table 6). The effectiveness of prior infection and vaccination 213 at reducing the hazard of symptomatic SARS-CoV-2 infection was highest following events 214 without documented exposure (HR: infection, 0.18 [0.07-0.45], vaccination, 0.21 [0.11-0.41]) 215 and lowest following cell exposure events (HR: infection, 0.42 [0.11-1.60], vaccination, 0.53 216 [0.17-1.64]). No residents with hybrid immunity had a symptomatic infection following a cell 217 exposure event (Supplement Figure 3; Unadjusted estimates: Supplement Table 5).

218 219 We performed sensitivity analyses that paralleled those described above (see
220 Supplement: Sensitivity Analyses). The effectiveness of prior infection and hybrid imm Supplement: Sensitivity Analyses). The effectiveness of prior infection and hybrid immunity was 221 highest following events without documented exposure and lowest following cell exposure

222 events under all scenarios (Supplement Figures 6, 8, 10, 12, 15, 17; Unadjusted estimates: Supplement Tables 10, 12, 14, 16, 19, 21). Vaccine effectiveness was highest following events 224 without documented exposures for all scenarios, except when we limited follow-up to nine days
225 (Supplement Figure 17: Unadiusted estimates: Supplement Table 21). Under this scenario, 225 (Supplement Figure 17; Unadjusted estimates: Supplement Table 21). Under this scenario,
226 vaccination reduced the hazard of infection by 0.31 (0.19-0.51) times following events witho vaccination reduced the hazard of infection by 0.31 (0.19-0.51) times following events without 227 documented exposure, 0.31 (0.21-0.46) times following cellblock exposure events, and 0.87
228 (0.45-1.69) times following cell exposure events. When we restricted to residents tested during 228 (0.45-1.69) times following cell exposure events. When we restricted to residents tested during 229 follow-up, the effectiveness of prior infection, vaccination, and hybrid immunity was highest
230 following events without documented exposure (HR: infection, 0.23 [0.12-0.42]; vaccination, 230 following events without documented exposure (HR: infection, 0.23 [0.12-0.42]; vaccination,
231 0.34 [0.22-0.52]; hybrid, 0.05 [0.01-0.11]) and lowest following cell exposure events (HR: 231 0.34 [0.22-0.52]; hybrid, 0.05 [0.01-0.11]) and lowest following cell exposure events (HR:
232 infection, 0.50 [0.25-0.98]; vaccination, 0.72 [0.37-1.41]; hybrid, 0.33 [0.12-0.91]; Supplen 232 infection, 0.50 [0.25-0.98]; vaccination, 0.72 [0.37-1.41]; hybrid, 0.33 [0.12-0.91]; Supplement 233 Figure 6; Unadjusted estimates: Supplement Table 10). Following the restriction to people 233 Figure 6; Unadjusted estimates: Supplement Table 10). Following the restriction to people 234 incarcerated since the beginning of the study, the effectiveness of prior infection, vaccination 234 incarcerated since the beginning of the study, the effectiveness of prior infection, vaccination,
235 and hybrid immunity was highest following events without documented exposure (HR: infectio and hybrid immunity was highest following events without documented exposure (HR: infection, 236 0.25 [0.13-0.48]; vaccination, 0.32 [0.19-0.54]; hybrid, 0.07 [0.02-0.18]) and lowest following cell 237 exposure events (HR: infection, 0.51 [0.25-1.03]; vaccination, 0.77 [0.38-1.58]; hybrid, 0.31
238 [0.10-0.99]; Supplement Figure 10; Unadjusted estimates: Supplement Table 14). [0.10-0.99]; Supplement Figure 10; Unadjusted estimates: Supplement Table 14).

239
240 240 During the Omicron period, the effectiveness of prior infection was highest following
241 events without documented exposure (HR: 0.36 [0.25-0.54]) and lowest following cell expos 241 events without documented exposure (HR: 0.36 [0.25-0.54]) and lowest following cell exposure 242 events (HR: 0.89 [0.58-1.35]). Vaccine effectiveness was highest following events without 243 documented exposure (HR: 0.57 [0.42-0.78]) and lowest following cell exposure events (HR: 244 0.96 [0.64-1.46]). The effectiveness of hybrid immunity was highest following events without 245 documented exposure (HR: 0.24 [0.15-0.39]) and lowest following cell exposure events (HR: 245 documented exposure (HR: 0.24 [0.15-0.39]) and lowest following cell exposure events (HR: 246 0.80 [0.46-1.39]). The effectiveness of prior infection, vaccination, and hybrid immunity was
247 significantly lower following cell exposure events than events without documented exposure 247 significantly lower following cell exposure events than events without documented exposure
248 (P=0.002, 0.041, and 0.001, respectively; Figure 4/Supplement Table 6). The effectiveness 248 (P=0.002, 0.041, and 0.001, respectively; Figure 4/Supplement Table 6). The effectiveness of 249 prior infection, vaccination, and hybrid immunity at reducing the hazard of symptomatic SARS-
250 CoV-2 infection was highest following events without documented exposure (HR: infection, 0.3 250 CoV-2 infection was highest following events without documented exposure (HR: infection, 0.35
251 [0.21-0.59]; vaccination, 0.33 [0.21-0.53]; hybrid, 0.13 [0.06-0.28]) and lowest following cell [0.21-0.59]; vaccination, 0.33 [0.21-0.53]; hybrid, 0.13 [0.06-0.28]) and lowest following cell 252 exposure events (HR: infection, 0.77 [0.45-1.31]; vaccination, 0.62 [0.35-1.10]; hybrid, 0.53 253 [0.26-1.11]; Supplement Figure 3; Unadjusted estimates: Supplement Table 5).

 $\frac{254}{255}$ 255 Following the restriction to residents tested during follow-up, the effectiveness of prior
256 infection, vaccination, and hybrid immunity was highest following events without documented infection, vaccination, and hybrid immunity was highest following events without documented exposures (HR: infection, 0.44 [0.30-0.63]; vaccination, 0.49 [0.36-0.68]; hybrid 0.32 [0.19-0.53]) and lowest following cell exposure events (HR: infection, 0.69 [0.47-1.02]; vaccination, 0.81 259 [0.53-1.22]; hybrid, 0.67 [0.44-1.02]; Supplement Figure 6; Unadjusted estimates: Supplement 260 Table 10). Following the restriction to people incarcerated since the study began, the Table 10). Following the restriction to people incarcerated since the study began, the 261 effectiveness of prior infection, vaccination, and hybrid immunity was highest following events
262 without documented exposures (HR: infection, 0.38 [0.24-0.58]; vaccination, 0.61 [0.43-0.86]; without documented exposures (HR: infection, 0.38 [0.24-0.58]; vaccination, 0.61 [0.43-0.86]; hybrid, 0.23 [0.14-0.38]) and lowest following cell exposure events (HR: infection, 0.88 [0.56- 1.37]; vaccination, 0.79 [0.49-1.28]; hybrid, 0.64 [0.39-1.05]; Supplement Figure 10; Unadjusted estimates: Supplement Table 14). The effectiveness of prior infection, vaccination, and hybrid immunity was highest following events without documented exposures and lowest following cell exposure events for each additional sensitivity analysis (Supplement Figures 8, 12, 15, 17; Unadjusted estimates: Supplement Tables 12, 16, 19, 21). 269

270 *SARS-CoV-2 exposure specific effects of prior infection and vaccination on*

271 *Infectiousness*

272 As a secondary analysis, we hypothesized that the prior infection and vaccination status
273 of the index cases may influence transmission. We examined this by restricting our sample to of the index cases may influence transmission. We examined this by restricting our sample to 274 cellblock and cell exposure events and comparing the hazards of infection when the index case
275 had and did not have the immunizing event of interest. During the Delta period, the prior 275 had and did not have the immunizing event of interest. During the Delta period, the prior
276 infection history of the index case was associated with a non-significantly higher hazard of 276 infection history of the index case was associated with a non-significantly higher hazard of 277 SARS-CoV-2 transmission following cellblock exposure events (HR: 1.96 [0.93-4.12]) and a 278 non-significantly lower hazard following cell exposure events (HR: 0.91 [95 CI: 0.20-4.18]). The 279 vaccination status of the index case was associated with a non-significantly lower hazard of 280 SARS-CoV-2 transmission among cellblock exposure events (HR: 0.75 [0.18-3.12]) and cell
281 exposure events (HR: 0.71 [0.26-1.93]; Figure 5). exposure events (HR: 0.71 [0.26-1.93]; Figure 5).

282 283 During the Omicron period, the prior infection status of the index case was associated
284 with a non-significantly lower hazard of SARS-CoV-2 transmission following cellblock exposure with a non-significantly lower hazard of SARS-CoV-2 transmission following cellblock exposure 285 events (HR: 0.52 [0.27-1.03]) and cell exposure events (HR: 0.72 [95 CI: 0.25-2.03]). The 286 vaccination history of the index case was associated with a non-significantly lower hazard of 287 SARS-CoV-2 transmission among cellblock exposure events (HR: 0.55 [0.24-1.24]) and cell
288 exposure events (HR: 0.52 [0.20-1.36]; Figure 5). exposure events (HR: 0.52 [0.20-1.36]; Figure 5).

289 **Discussion**

291 Leveraging the controlled social structure and detailed epidemiological data of correctional
292 facilities, we found that residents with close (cell) exposures and moderate (cellblock) facilities, we found that residents with close (cell) exposures and moderate (cellblock) 293 exposures to SARS-CoV-2 infected residents had a significantly higher risk of becoming 294 infected with SARS-CoV-2 than residents without a documented exposure during Delta and
295 Omicron periods. Further, we found that prior SARS-CoV-2 infection, COVID-19 vaccination. 295 Omicron periods. Further, we found that prior SARS-CoV-2 infection, COVID-19 vaccination, 296 and hybrid immunity (prior infection and vaccination) significantly reduced the risk of infection
297 among residents with cellblock exposures and without documented exposures, but not resider 297 among residents with cellblock exposures and without documented exposures, but not residents
298 with cell exposures during both periods. Finally, we found that the vaccination status of the 298 with cell exposures during both periods. Finally, we found that the vaccination status of the
299 index case was associated with a non-significant reduction in the risk of secondary SARS-C 299 index case was associated with a non-significant reduction in the risk of secondary SARS-CoV-
300 2 cases following cell and cellblock exposures during Delta and Omicron periods. 2 cases following cell and cellblock exposures during Delta and Omicron periods.

301
302

302 Our findings indicate that exposure to an infected resident in a cell or cellblock significantly
303 increased the risk of becoming infected with SARS-CoV-2 and supports the benefit of contact 303 increased the risk of becoming infected with SARS-CoV-2 and supports the benefit of contact
304 tracing within the cell and cellblock of infected residents. These findings held irrespective of the 304 tracing within the cell and cellblock of infected residents. These findings held irrespective of the
305 period when differing variants were circulating. However, the magnitude of the cell exposure 305 period when differing variants were circulating. However, the magnitude of the cell exposure
306 effect was smaller during the Omicron period than the Delta period, potentially due to the effect was smaller during the Omicron period than the Delta period, potentially due to the 307 increased transmissibility of the Omicron variant.^{25–27} Despite the observed decline in effect 308 size, cellblock or cell exposures increased the hazard of infection by 3.3 and 4.7 times during 309 the Omicron period, respectively. These findings speak to the continued need for contact tracing
310 within correctional facilities and other high-density settings, including nursing homes, and within correctional facilities and other high-density settings, including nursing homes, and 311 suggest that contact tracing should not be limited to residents of the same cell but include
312 residents that interact during recreation and meals, as is the case among residents of the s 312 residents that interact during recreation and meals, as is the case among residents of the same
313 cellblock within Connecticut DOC run facilities. cellblock within Connecticut DOC run facilities.

 $\frac{314}{315}$ During both the Delta and Omicron periods, we found that neither prior infection, nor 316 vaccination, nor hybrid immunity provided significant levels of protection against SARS-CoV-2 317 infection following cell exposure events and that the levels of protection were significantly 318 smaller following cell exposure events than following events without documented exposures. 319 Further, despite having a limited sample during the period of Delta predominance, we observed
320 similar gradients in the level of protection offered by prior infection, vaccination, and hybrid 320 similar gradients in the level of protection offered by prior infection, vaccination, and hybrid
321 immunity against symptomatic infection. These findings provide empirical evidence that, wh immunity against symptomatic infection. These findings provide empirical evidence that, while 322 accounting for factors thought to be associated with vaccine acceptance and infection, the

323 protection offered by prior infection, vaccination, and hybrid immunity, appears to be leaky. They
324 suggest that there may be an additional mechanism, based on the intensity of the infectious suggest that there may be an additional mechanism, based on the intensity of the infectious 325 exposure, which may explain observed, partial levels of immunity conferred by infection and
326 vaccination, in addition to factors such as variant-specific immune escape, waning immunity 326 vaccination, in addition to factors such as variant-specific immune escape, waning immunity and 327 reduced effectiveness in specific subpopulations, such as older people.^{28–30} reduced effectiveness in specific subpopulations, such as older people. $28-30$

328
329

Beyond providing an evidence base for the mechanism by which prior SARS-CoV-2 330 infections and COVID-19 vaccines confer immunity, these findings have broad implications on 331 SARS-CoV-2 transmission modeling, vaccine effectiveness analyses, and prevention strategy
332 development. Though most SARS-CoV-2 transmission models likely incorporate a simplifying 332 development. Though most SARS-CoV-2 transmission models likely incorporate a simplifying
333 assumption that the vaccines provide leaky protection,^{31,32} the validity of this assumption has n 333 assumption that the vaccines provide leaky protection, $31,32$ the validity of this assumption has not 334 been previously documented with empirical data and model parameterization based 334 been previously documented with empirical data and model parameterization based examinations were found to be inconclusive.³¹ Thus, our findings provide evidence the examinations were found to be inconclusive. 31 Thus, our findings provide evidence that this 336 assumption may be valid. They also indicate that when estimating future disease burdens u assumption may be valid. They also indicate that when estimating future disease burdens under 337 scenarios of defined exposures, modelers may need to account for the reduced effectiveness of 338 prior infections and vaccinations among modeled participants with prolonged, close
339 exposures.^{31,32} Furthermore, theoretical studies have demonstrated that the efficacy 339 exposures.^{31,32} Furthermore, theoretical studies have demonstrated that the efficacy of leaky
340 vaccines is underestimated by common study designs, which may contributes to variation in 340 vaccines is underestimated by common study designs, which may contributes to variation in 341 observed vaccine effectiveness across settings.^{17,33} observed vaccine effectiveness across settings.^{17,33}

342

343 These findings also suggest the benefit of layered interventions in general, and particularly 344 within densely packed social settings. In the presence of leaky vaccines, non-pharmaceutical 345 interventions have been proposed in tandem with vaccination in order to reduce exposure and 346 mitigate infection spread.³⁴ Such interventions may include social distancing, quarantine and mitigate infection spread.³⁴ Such interventions may include social distancing, quarantine and 347 isolation, masking, and improved ventilation and airflow.^{35,36} While our findings are obtained 348 from the investigation of a correctional facility system, in the presence of a leaky vaccine,
349 layered interventions may afford a benefit in other congregate settings and community set layered interventions may afford a benefit in other congregate settings and community settings 350 where prolonged, close contact with infected people may occur, such as mass gatherings. 351

352 If the protection offered by vaccination is indeed leaky, the increased transmissibility of the 353 Omicron variant may have contributed to the well documented decline in the effectiveness of vaccination during periods of Omicron predominance.^{26,27,37} In alignment with prior studies and vaccination during periods of Omicron predominance.^{26,27,37} In alignment with prior studies and 355 this speculation, we observed lower levels of protection during the Omicron period. Though this 356 decline has been primarily attributed to variant specific immune escape due to the large number 356 decline has been primarily attributed to variant specific immune escape due to the large number 357 of mutations present in the spike protein, $37-39$ the high transmissibility of the Omicron variant of mutations present in the spike protein, $37-39$ the high transmissibility of the Omicron variant 358 may have resulted in high enough exposure levels (pathogen pressure) in the community to 359 enhance the effects of leaky protection in populations that experienced prior SARS-CoV-2 360 infection and/or vaccination. This speculation invokes the question of whether layered 361 interventions would provide increased benefit in general settings, not just within densely packed 362 settings, when highly transmissible variants are circulating.

363
364 We found that hybrid immunity offered the highest level of protection, followed by prior 365 infection. While this finding aligns with prior studies, $40-42$ the observed differences in the level of 366 protection may reflect the recency of prior infections compared to vaccination (due to an artificial 367 truncation of the time since infection resulting from the absence of community infection data). 368 However, the absence of community infection data results in prior infection misclassification 369 and, alternatively, may have resulted in conservative effectiveness estimates for prior infection.
370 To examine the impact of these missing data, we conducted a sensitivity analysis limited to 370 To examine the impact of these missing data, we conducted a sensitivity analysis limited to 371 residents incarcerated since June 15, 2021 (study beginning). Relative to the primary analys 371 residents incarcerated since June 15, 2021 (study beginning). Relative to the primary analysis, we did not observe a specific directional shift in the effectiveness estimates, and we observed a 373 similar gradient in the levels of protection by facility exposure. Though, data limitations

374 prevented us from performing this analysis among people incarcerated since the beginning of 375 the pandemic, infection-induced seroprevalence estimates from Connecticut suggest that only the pandemic, infection-induced seroprevalence estimates from Connecticut suggest that only a 376 small proportion of the population had been infected as of July 2021 (4.7-19.7%) and the 377 residual bias is likely limited.^{43,44} residual bias is likely limited. $43,44$

378

379 Our effect estimates on infectiousness during the Omicron period are in alignment with a
380 prior study by Tan et al.⁴⁵ This study conducted in California correctional facilities, found that prior study by Tan et al.⁴⁵ This study conducted in California correctional facilities, found that the 381 prior infection and vaccination status of an index case reduced the risk of transmission by 40% 382 (20-55%) and 22% (6-36%), respectively. Similarly, we found that the risk of transmission 383 following a cell exposure was 0.72 (0.25-2.03) times lower among infected residents with a prior
384 infection and 0.52 (0.2-1.36) times lower among infected residents with a history of vaccination 384 infection and 0.52 (0.2-1.36) times lower among infected residents with a history of vaccination
385 than residents without a prior infection or history of vaccination. Though our precision prevents 385 than residents without a prior infection or history of vaccination. Though our precision prevents 386 us from making broad conclusions from these findings, they support the findings of Tan et al.⁴⁵ us from making broad conclusions from these findings, they support the findings of Tan et al.⁴⁵ 387

388 We acknowledge that our study was subject to several limitations. A key potential limitation 389 stems from testing related differences following events with and without documented exposures.
390 Though the Connecticut DOC has, and continues to, conduct intensive COVID-19 testing, 390 Though the Connecticut DOC has, and continues to, conduct intensive COVID-19 testing,
391 testing is more common among residents with an infected cellmate than residents without 391 testing is more common among residents with an infected cellmate than residents without a
392 documented exposure (Figure 1.C) and may result in an overestimation of the effect of cell of 392 documented exposure (Figure 1.C) and may result in an overestimation of the effect of cell or
393 cellblock exposures. While we did observe an attenuation towards the null following the cellblock exposures. While we did observe an attenuation towards the null following the 394 restriction to people who were tested during follow-up, this restriction did not remove the 395 observed gradient in the levels of protection conferred by prior infection, vaccination, or hybrid 396 immunity by facility exposure. In addition to testing frequency, we were concerned that 397 differences in the proportion of tests conducted as a result of symptoms may have intro differences in the proportion of tests conducted as a result of symptoms may have introduced 398 bias into our analysis (Supplement Figure 4). However, very few tests were performed for
399 symptomatic reasons and we continued to find the levels of protection to be highest follow 399 symptomatic reasons and we continued to find the levels of protection to be highest following
400 events without documented exposures and lowest following cell exposure events. events without documented exposures and lowest following cell exposure events.

401

402 Another potential source of testing related bias stems from the contact tracing protocol.
403 During the study period, the contact tracing protocol remained consistent and followed the During the study period, the contact tracing protocol remained consistent and followed the recommendations of the CDC (see Supplement DOC COVID-19 Testing). 46 The protocol stated 405 that close contacts should be tested five days after contact. however, variation in the exact day that close contacts should be tested five days after contact, however, variation in the exact day 406 of testing was probable. Because rapid antigen tests (the test used for contact tracing) are 407 highly sensitive to the viral load, residents tested too soon or long after a contact may have 407 highly sensitive to the viral load, residents tested too soon or long after a contact may have a
408 false negative test, especially if they have a history of prior infection or vaccination (which false negative test, especially if they have a history of prior infection or vaccination (which 409 reduces the viral load).⁴⁷ If variation in the time between contact and testing existed between 410 events without documented exposure, cellblock exposure events, and cell exposure events, 411 upward or downward bias may have been introduced. Testing prioritization is another potential source of bias from contact tracing. However, due to the testing capacity, contact tracing was 413 performed among symptomatic and asymptomatic residents with or without history of prior
414 infections or vaccination and no prioritization was required. infections or vaccination and no prioritization was required.

415

416 Our analysis was conducted in a single DOC system and the findings may not be 417 generalizable to all correctional facility settings. Further, we did not have testing or infection data 418 for staff, nor did we have comorbidity and masking data for residents and symptom data for RT-419 PCR tests. The absence of comorbidity data may result in biased estimates of effectiveness as 420 residents with comorbidities are more likely to become vaccinated and may be more or less
421 likely to become infected with SARS-CoV-2, depending on differential behaviors. However, 421 likely to become infected with SARS-CoV-2, depending on differential behaviors. However,
422 through adjusting for age and race, we may have accounted for a part of the confounding et 422 through adjusting for age and race, we may have accounted for a part of the confounding effect
423 of comorbidities. Due to the absence of symptom data for RT-PCRs, we defined symptomatic of comorbidities. Due to the absence of symptom data for RT-PCRs, we defined symptomatic 424 infection as a symptomatic rapid antigen test, thus assuming RT-PCR detected infections were

425 asymptomatic. Data limitations prevented us from examining the leakiness of immunity-
426 conferring events against severe outcomes and future analyses with complete symptom

- 426 conferring events against severe outcomes and future analyses with complete symptomatic and 427 severe outcomes data should examine leakiness relative to these outcomes.
-

428
429 Due to sample limitations, we were unable to stratify vaccination and prior infection status by 430 time since vaccination. However, we found no significant difference in the time since prior 431 infection or vaccination between residents with events with and without documented exposures. 432 Behavioral differences between people with prior infections or who have been vaccinated may 433 differ from people without a prior infection or vaccination. While this may have led to either an
434 over or under estimation of the effect of cell or cellblock exposures, it should not have driven c 434 over or under estimation of the effect of cell or cellblock exposures, it should not have driven our 435 findings suggesting leakiness. Finally, while we conducted numerous sensitivity analyses to 435 findings suggesting leakiness. Finally, while we conducted numerous sensitivity analyses to
436 examine the robustness of our findings, we were unable to account for all potential sources 436 examine the robustness of our findings, we were unable to account for all potential sources of 437 bias at the same time and residual bias may be present within our findings. bias at the same time and residual bias may be present within our findings.

438
439

This study provides empiric evidence that COVID-19 vaccination and prior infection confer 440 exposure dependent ("leaky") protection against SARS-CoV-2 infections. The findings support 441 the use of leaky vaccine parameters in SARS-CoV-2 transmission modeling and indicate the 441 the use of leaky vaccine parameters in SARS-CoV-2 transmission modeling and indicate the 442 need for modelers to account for the reduced protection conferred by prior infection and need for modelers to account for the reduced protection conferred by prior infection and
443 vaccinations among people with prolonged, close exposures. Further, our findings sugge 443 vaccinations among people with prolonged, close exposures. Further, our findings suggest the
444 need for layered interventions to mitigate SARS-CoV-2 spread, especially within dense settings need for layered interventions to mitigate SARS-CoV-2 spread, especially within dense settings, 445 such as congregate settings, and in settings where prolonged contact is likely, such as 446 households with infected people.

447
448

Methods

449
450

450 *Population and Data* We conducted a rolling matched cohort analysis among residents of Connecticut DOC 452 facilities who were incarcerated between June 15, 2021, when Delta became the predominant variant in Connecticut according to sequenced clinical samples, and May 10, 2022.²⁴ Resident 454 demographic (age, race, gender), housing (daily facility, cellblock [block of cells or dorm], cell o demographic (age, race, gender), housing (daily facility, cellblock [block of cells or dorm], cell or 455 dorm, and bunk), and COVID-19 testing, and vaccination data were extracted from DOC 456 maintained databases containing data collected as part of routine SARS-CoV-2 surveillance. 457 Testing records included all rapid antigen (primarily BinaxNOW) and RT-PCR (primarily 458 analyzed by Quest) tests administered within a DOC operated facility since the beginnin 458 analyzed by Quest) tests administered within a DOC operated facility since the beginning of the
459 pandemic. We excluded residents who never spent a night in a cell with at least one cellmate. pandemic. We excluded residents who never spent a night in a cell with at least one cellmate, 460 spent less than 14 days incarcerated, or resided exclusively within a restricted housing 461 cellblock.

462

463 The research was performed by researchers at the Connecticut Department of 464 Correction and Yale University (located within the state of Connecticut). All roles and
465 responsibilities were determined by the collaborating researchers ahead of analysis a responsibilities were determined by the collaborating researchers ahead of analysis and the 466 questions raised were done so collectively. The study was determined to be a public health 467 surveillance activity by the Yale University Institutional Review Board and exempt from review 468 (ID: 2000031675). The study results do not stigmatize, incriminate, or discriminate the 469 participants. Our citation list includes research previously published by this collaborative group 470 regarding testing policies within the CT DOC and seroprevalence studies from CT (not from this 471 group).

472

473 *Department of Correction COVID-19 Protocols* Since the introduction of COVID-19 in the winter of 2019-2020, the Connecticut DOC 475 has implemented numerous COVID-19 prevention strategies including testing (rapid antigen

476 and RT-PCR), masking, isolation/quarantine, and vaccination. As part of their COVID-19
477 mitigation strategy, the DOC restricted the interaction of residents during meal and recrea mitigation strategy, the DOC restricted the interaction of residents during meal and recreation 478 time to residents of the same cellblock. Thus, during the study period, residents of the same
479 cellblock interacted with other residents of their cellblock during meal and recreation times bu 479 cellblock interacted with other residents of their cellblock during meal and recreation times but,
480 unless their employment required them to move throughout the facility, the residents did not 480 unless their employment required them to move throughout the facility, the residents did not 481 interact with residents of different cellblocks. However, DOC staff continued to move throughout 482 the facilities and were placed in different cellblocks on different days. the facilities and were placed in different cellblocks on different days.

483

484 Masks are required for all residents while outside of their cell or, if residing in a dorm,
485 moving around their dorm. This is analogous to a non-incarcerated person wearing a mask 485 moving around their dorm. This is analogous to a non-incarcerated person wearing a mask
486 while socializing in public but not having to wear a mask within their home. Testing with RT-486 while socializing in public but not having to wear a mask within their home. Testing with RT-
487 PCRs was and continues to be conducted primarily for mass testing. Testing with rapid antic 487 PCRs was and continues to be conducted primarily for mass testing. Testing with rapid antigen
488 test was and continues to be conducted for five primary reasons: intakes/transfers, 488 test was and continues to be conducted for five primary reasons: intakes/transfers,
489 symptomatic, employment, and contact tracing.^{48,49} Among residents of cells, conta symptomatic, employment, and contact tracing.^{48,49} Among residents of cells, contact tracing 490 included testing all residents of the same cell as the infected resident and residents of the same 491 cellblock or facility but only if close contact was reported by the infected resident. Close contact 492 was defined in accordance with the CDC definition (being within six feet for at least 15 minutes 492 was defined in accordance with the CDC definition (being within six feet for at least 15 minutes 493 within a 24-hour period).⁴⁶ Resident testing as part of mass screening is considered optional bur within a 24-hour period).⁴⁶ Resident testing as part of mass screening is considered optional but 494 requiar testing is required for many within facility jobs as well as some community facing jobs. 494 regular testing is required for many within facility jobs as well as some community facing jobs.
495 The specific testing requirements vary by position. Residents who test positive for SARS-CoV 495 The specific testing requirements vary by position. Residents who test positive for SARS-CoV-2
496 are moved to isolation the dav they test positive. For details on testing see Supplement: DOC are moved to isolation the day they test positive. For details on testing see Supplement: DOC 497 COVID-19 Testing.

498
499

A detailed description of the vaccination program can be found elsewhere.^{49,50} Briefly, 500 the DOC began their COVID-19 vaccination program on February 2^{nd} , 2021 and provided 501 vaccines to residents who qualified for vaccination according to state-defined eligibility and were
502 not actively infected. Residents who were partially vaccinated were offered second or not actively infected. Residents who were partially vaccinated were offered second or 503 subsequent doses of the corresponding vaccine. Vaccinations received prior to incarceration 504 were verified using CT WiZ, Connecticut's COVID-19 vaccine registry.⁵⁰

505

506 *Sample, Type of SARS-CoV-2 Exposure, Follow-up and Matching*

For each resident, we identified the days they were housed in a cell. We excluded the first 14 days a person was in the study along with days a resident was housed in a restricted 509 housing cellblock, had an undefined housing location, or did not have at least one roommate.
510 Additionally, to prevent the inclusion of the same infection more than once, we excluded Additionally, to prevent the inclusion of the same infection more than once, we excluded resident days in the 90 days following a positive SARS-CoV-2 infection.

512

513 On each included day, residents were classified as having one of three facility structure
514 defined SARS-CoV-2 exposure event types: cell exposure event, cellblock exposure event, or 514 defined SARS-CoV-2 exposure event types: cell exposure event, cellblock exposure event, or 515 events without documented exposure. We classified a resident as having a cell exposure event for 516 if at
516 if at least one of their cellmates tested positive for SARS-CoV-2, a cellblock exposure event if at 516 if at least one of their cellmates tested positive for SARS-CoV-2, a cellblock exposure event if at 517 least one resident of the same cellblock but different cell tested positive for SARS-CoV-2, or an least one resident of the same cellblock but different cell tested positive for SARS-CoV-2, or an 518 event without documented exposure if no one in their cellblock tested positive for SARS-CoV-2 519 (Supplement Figure 1). We excluded cell exposure events that occurred within 14 days of a 520 prior cell exposure event and cellblock exposure events and events without documented 521 exposures that occurred within 14 days of a prior cellblock or cell exposure event. Further, to 522 remove the risk of including multiple events without documented exposures from the same
523 resident during a 14-day period, we randomized the sample of residents with events withou 523 resident during a 14-day period, we randomized the sample of residents with events without
524 documented exposures and dropped all days for each person within 14 days of the selected 524 documented exposures and dropped all days for each person within 14 days of the selected
525 date. Following this exclusion, we cluster matched the cell exposure events, cellblock exposu date. Following this exclusion, we cluster matched the cell exposure events, cellblock exposure 526 events and events without documented exposures on facility (exact) and calendar date (+/- 7

527 days). This ensured that each exposure group was observed at the same time and in the same 528 facility. facility.

529
530 530 Residents were defined as becoming infected with SARS-CoV-2 if they tested positive
531 during the 14 days following inclusion.⁴⁵ We censored resident time on the date of release or during the 14 days following inclusion.⁴⁵ We censored resident time on the date of release or 532 death or when a resident became exposed at a more proximal level (ex. resident with a
533 cellblock exposure was exposed within their cell). This sampling schematic allowed for r cellblock exposure was exposed within their cell). This sampling schematic allowed for residents 534 to be included in the analysis multiple times for the same or different facility exposure statuses. 535 The sample was then stratified by variant predominance within Connecticut (Delta: June 15,
536 2021, through December 12, 2021; Omicron: December 13, 2021, through the end of the stu 536 2021, through December 12, 2021; Omicron: December 13, 2021, through the end of the study
537 [May 10, 2022]).²⁴ We stratified this analysis by variant predominance due to differences in the [May 10, 2022]).²⁴ We stratified this analysis by variant predominance due to differences in the transmissibility of the variants and the levels of protection offered by prior infections and 538 transmissibility of the variants and the levels of protection offered by prior infections and vaccinations against the variants.^{15,26,38} vaccinations against the variants. $15,26,38$

540

541 *Prior Infection, Vaccination and Hybrid Immunity Status*

542 We identified the prior infection, vaccination, and hybrid immunity status of residents with
543 cell exposure events, cellblock exposure events, and events without documented exposure. 543 cell exposure events, cellblock exposure events, and events without documented exposure.
544 Additionally, we identified the prior infection, vaccination, and hybrid immunity status of the 544 Additionally, we identified the prior infection, vaccination, and hybrid immunity status of the
545 index cases (infected residents that resulted in all cell and cellblock exposures). We classifi 545 index cases (infected residents that resulted in all cell and cellblock exposures). We classified a
546 person as being vaccinated if they had received at least one COVID-19 vaccine dose, person as being vaccinated if they had received at least one COVID-19 vaccine dose, 547 regardless of the brand or time since the dose was administered. We defined a prior infection as 548 a positive, recorded SARS-CoV-2 rapid antigen or RT-PCR test collected in a DOC facility at 549 least 90 days prior to the date of inclusion. Hybrid immunity was defined as a person having
550 received at least one vaccine dose and having had at least one prior infection as of the date received at least one vaccine dose and having had at least one prior infection as of the date of 551 inclusion. 552

553 *Statistical Analysis*

554 We visually summarized the vaccine coverage, number of COVID-19 tests and number 555 of SARS-CoV-2 infections recorded among DOC residents during the study period. We 556 summarized the resident characteristics of cell exposure events, cellblock exposure events, and 557 events without documented exposures using medians, first and third quartiles, counts and
558 percentages. Resident gender is evaluated at intake by correctional officers and designate 558 percentages. Resident gender is evaluated at intake by correctional officers and designated
559 based on genitalia (observed during intake strip search) and governmental documents 559 based on genitalia (observed during intake strip search) and governmental documents
560 (passport, driver's license, and birth certificate). We compared the time since last prior 560 (passport, driver's license, and birth certificate). We compared the time since last prior infection
561 and vaccine dose using linear models adjusted for age, race, time of inclusion, room size, and and vaccine dose using linear models adjusted for age, race, time of inclusion, room size, and 562 cellblock (mirroring the adjustment factors included in the primary analyses, see Facility 563 Exposure Specific Effects of Prior Infection, Vaccination, and Hybrid Immunity on Susceptibility). 564 Data cleaning, management, and analyses were conducted in R version 4.2.1.

565
566 566 *Association Between Facility Exposure and SARS-CoV-2 Infection Risk*

We estimated the association between known SARS-CoV-2 exposure and SARS-CoV-2 568 infection risk using a facility stratified Cox Proportional Hazards model with an outcome of test 569 positive SARS-CoV-2 infection, a primary exposure of type of facility exposure (cell exposure
570 events, cellblock exposure events, or events without documented exposure). Further, to accou events, cellblock exposure events, or events without documented exposure). Further, to account 571 for the correlation of events among people residing within the same cellblock, we estimated 572 confidence intervals using robust standard errors. The model was adjusted for the following a 573 priori selected potential confounders (Supplement Figure 18): calendar time (continuous), age
574 (continuous), self-identified race (non-Hispanic Black, non-Hispanic White, Other), and room 574 (continuous), self-identified race (non-Hispanic Black, non-Hispanic White, Other), and room
575 and cellblock size (continuous). Continuous variables were modeled flexibly using natural 575 and cellblock size (continuous). Continuous variables were modeled flexibly using natural
576 splines. Though gender is a potential confounder, facilities contain residents of only a sing splines. Though gender is a potential confounder, facilities contain residents of only a single

577 gender and all contrast was eliminated by facility stratification. Significance was defined with an 578 alpha of 0.05 and determined using two-sided z-tests. alpha of 0.05 and determined using two-sided z-tests.

579 580 *Facility Exposure Specific Effects of Prior Infection, Vaccination, and Hybrid Immunity on* 581 *Susceptibility*

582 We estimated the association between prior infection and infection risk using a cellblock 583 stratified Cox Proportional Hazards model with robust standard errors, an outcome of SARS-584 CoV-2 infection, a primary exposure of prior infection history, and an interaction term between 585 facility exposure type and prior infection history. The model was adjusted for the calendar time
586 (continuous), age (continuous), staff assigned race, room size (continuous), and the vaccinatio 586 (continuous), age (continuous), staff assigned race, room size (continuous), and the vaccination
587 history of the susceptible resident. The effect of vaccination was examined using the same 587 history of the susceptible resident. The effect of vaccination was examined using the same
588 model but with an exposure of vaccination instead of prior infection and an adjustment facto 588 model but with an exposure of vaccination instead of prior infection and an adjustment factor of 589 prior infection. We estimated the effect of hybrid immunity using the same model but with an 589 prior infection. We estimated the effect of hybrid immunity using the same model but with an 590 exposure of hybrid immunity. This analysis was restricted to residents with either hybrid exposure of hybrid immunity. This analysis was restricted to residents with either hybrid 591 immunity or no history of prior infection or vaccination. We tested if the hazard ratios of cell and 592 cellblock exposure events were significantly different than the hazard ratio for events without
593 documented exposures using two-sided z-tests and defined significance with an alpha of 0.05 593 documented exposures using two-sided z-tests and defined significance with an alpha of 0.05.
594 As a secondary analysis, we estimated the effect of prior infection, vaccination, and hybrid 594 As a secondary analysis, we estimated the effect of prior infection, vaccination, and hybrid
595 immunity on the hazard of symptomatic infection. Due to an absence of symptomatic data f 595 immunity on the hazard of symptomatic infection. Due to an absence of symptomatic data for
596 RT-PCR tests, we defined symptomatic infection as a positive rapid antigen test collected fror 596 RT-PCR tests, we defined symptomatic infection as a positive rapid antigen test collected from
597 a symptomatic resident. We used the same models for these analyses as we did for the a symptomatic resident. We used the same models for these analyses as we did for the 598 infection outcome analyses.

599 600 *Facility Exposure Specific Effects of Prior Infection and Vaccination on Infectiousness*

601 As a secondary analysis, we were interested in evaluating the impact the index cases' 602 history of prior infection and vaccination had on the risk of SARS-CoV-2 infection among 602 history of prior infection and vaccination had on the risk of SARS-CoV-2 infection among
603 residents with cellblock and cell exposure events. For this analysis, we restricted our sam residents with cellblock and cell exposure events. For this analysis, we restricted our sample to residents with facility exposures. If residents were exposed to multiple index cases on the same day, we restricted to residents who were exposed to index cases with the same prior infection and vaccination histories. We estimated the effect of prior infection on infectiousness using a cellblock stratified Cox Proportional Hazards model with robust standard errors. The model had an outcome of SARS-CoV-2 infection, an exposure of the index case's prior infection history, 609 and an interaction term between facility exposure type and the index case's prior infection
610 history. The model was adjusted for the same factors as the susceptibility analysis model a history. The model was adjusted for the same factors as the susceptibility analysis model and the vaccination history of the index case. The effect of vaccination was examined using the same model but with a primary exposure of the index case's vaccination history instead of prior infection history.

614
 615 615 *Sensitivity Analyses*

616 To test the robustness of our findings to alternative study design, data cleaning, and
617 modeling assumptions, we conducted multiple sensitivity analyses (Supplement: Sensitivity modeling assumptions, we conducted multiple sensitivity analyses (Supplement: Sensitivity Analyses). Of particular concern was biases due to differences in testing frequency or reasons for testing among residents with and without cell or cellblock exposures. To examine the impact of potential testing bias, we conducted two sensitivity analyses. First, we restricted to residents tested during follow-up. Second, because symptoms are associated with the level of protection conferred by prior infections and vaccinations, we performed an additional analysis which excluded residents tested due to symptoms (reason for testing listed as symptomatic).

624
625 625 In addition to concerns around testing related biases, we were concerned that the
626 absence of community infection data may have resulted in biased effectiveness estimates absence of community infection data may have resulted in biased effectiveness estimates for 627 prior infections. We examined the impact of this missing data by limiting our sample to people 628 incarcerated since the beginning of the study (June 15, 2021). Additionally, we were concerned
629 that we may have overestimated the association between documented SARS-CoV-2 exposure that we may have overestimated the association between documented SARS-CoV-2 exposure 630 and infection risk by including residents' exposure to multiple infected residents in their cell or 631 cellblock on the same day. To examine this, we conducted a sensitivity analysis restricted to c 631 cellblock on the same day. To examine this, we conducted a sensitivity analysis restricted to cell
632 and cellblock exposure events where only one index case was observed. Further, to ensure that and cellblock exposure events where only one index case was observed. Further, to ensure that 633 our decision to include residents without recent negative tests did not drive our findings, we 634 conducted a sensitivity analysis restricted to residents who tested negative in the prior five days. 635 Additionally, we wanted to ensure our exposures were temporally linked to observed infections. 636 To do so, we conducted two sensitivity analyses: one excluding the first 2 days of follow-up, and 637 one limiting follow-up to nine days. For a detailed description of sensitivity analyses performed see Supplement: Sensitivity Analyses. 639

640

- **Data Availability:** The data used in this study belongs to the Connecticut Department of 642 Correction and cannot be shared publicly because of the presence of potentially identifiable
- Correction and cannot be shared publicly because of the presence of potentially identifiable
- 643 health and resident information. Qualified researchers may request for de-identified, patient 644 level data by contacting the corresponding author with a detailed description of the research
- 644 level data by contacting the corresponding author with a detailed description of the research
645 guestion and setting up a data use agreement with the Connecticut Department of Correction
- question and setting up a data use agreement with the Connecticut Department of Correction.
- 646
647
- 647 **Code Availability:** Code generated to conduct the statistical analyses is available in the 648 following repository: https://github.com/lindm89/CT DOC Dose Effect Vax.git.⁵¹
- following repository: https://github.com/lindm89/CT_DOC_Dose_Effect_Vax.git.⁵¹

References

-
-
- 1. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. 3.

2. WHO. *Vaccine efficacy, effectiveness and protection*. https://www.who.int/news-

room/feature-stories/detail/vaccine-effic WHO. *Vaccine efficacy, effecti*
room/feature-stories/detail/va
Thomas, S. J. *et al*. Safety and
Months. *N. Engl. J. Med.* **385**,
Walsh, E. E. *et al.* Safety and Ir
Candidates. *N. Engl. J. Med.* **3**8 2. WHO. Vaccine efficacy, effectiveness and protection. https://www.who.int/news-
room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection (2021)
3. Thomas, S. J. *et al.* Safety and Efficacy of the BNT162
-
- room, results-stories, acting and the proton of the BNT162b2 mRNA Covid-19 Vaccine th
Months. *N. Engl. J. Med.* 385, 1761–1773 (2021).
Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine
Cand 3. Thomas, S. J. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6
3. Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine
Candidates. *N. Engl. J. Med.* 383, 2439–2450
- Wolffins. *N. Engl. J. Med.* 385, 1701–1775 (2021).
Walsh, E. E. *et al.* Safety and Immunogenicity of T
Candidates. *N. Engl. J. Med.* **383**, 2439–2450 (202
Baden, L. R. *et al.* Efficacy and Safety of the mRNA
Med. **384** 4. Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine

Candidates. N. Engl. J. Med. 383, 2439–2450 (2020).

5. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Candidates. *N. Engl. 3. Med.* 383, 2433–2430 (2020).
Baden, L. R. *et al.* Efficacy and Safety of the mRNA-12
Med. 384, 403–416 (2021).
Gazit, S. *et al.* Severe Acute Respiratory Syndrome Co
Acquired Immunity versus Va 5. Baden, L. R. et al. Emcacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. 3.

Med. 384, 403-416 (2021).

6. Gazit, S. et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally

Acquired Imm Med. 384, 403–416 (2021).
Gazit, S. *et al.* Severe Acute
Acquired Immunity versus \
Infections: A Retrospective
e545–e551 (2022).
Tillett, R. L. *et al.* Genomic e 6. Gazit, S. et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally
Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough
Infections: A Retrospective Cohort Study. *Clin* Infections: A Retrospective Cohort Study. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 7
e545–e551 (2022).
Tillett, R. L. *et al.* Genomic evidence for reinfection with SARS-CoV-2: a case study. *Lancet*
Infect.
-
- Infections: A Retrospective Cohort Study. Clin. Inject. Dis. Off. Publ. Infect. Dis. Soc. Am. 75,
e545-e551 (2022).
I illett, R. L. *et al.* Genomic evidence for reinfection with SARS-CoV-2: a case study. *Lancet*
Infect. Tillett, R. L. *et al*. Ge
Infect. Dis. **21**, 52–5
Sotoodeh Ghorbani
recurrence, and hos
analysis. J. Med. Vir 7. Timet, R. L. et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet

Infect. Dis. 21, 52–58 (2021).

8. Sotoodeh Ghorbani, S. et al. Epidemiologic characteristics of cases with reinfection,

recur Infect. Dis. 21, 52–58 (2021).
Sotoodeh Ghorbani, S. *et al.* I
recurrence, and hospital read
analysis. *J. Med. Virol*. **94**, 44-8. Sotooden Ghorbani, S. et al. Epidemiologic characteristics of cases with reinfection,
recurrence, and hospital readmission due to COVID-19: A systematic review and me
analysis. J. Med. Virol. 94, 44–53 (2022). analysis. J. Med. Virol. 94, 44–53 (2022).
-
- 9. Pienfections: Overview of efficacy and duration of natural and hybrid immunity. Envines.

9. Phys. 209, 112911 (2022).

10. Lind, M. L. et al. Use of whole genome sequencing to estimate the contribution of in

9. evasio remections: Overview of efficacy and duration of natural and hybrid immunity. Environ.
Res. 209, 112911 (2022).
Lind, M. L. *et al.* Use of whole genome sequencing to estimate the contribution of immun
evasion and waning i Res. 209, 112911 (2022).
Lind, M. L. *et al*. Use of w
evasion and waning immu
and delta variant waves.
https://doi.org/10.1101/.
Grewal, R. *et al*. Effective
mRNA Vaccine among Lo 10. Lind, M. L. et al. Use of whole genome sequencing to estimate the contribution of immune

10. Lind, M. L. et al. Use of whole genome sequencing to estimate the contribution of immune

11. Grewal, R. et al. Effectivenes
- evasion and delta variant waves. 2022.08.25.22278443 Preprint at
https://doi.org/10.1101/2022.08.25.22278443 (2022).
Grewal, R. *et al.* Effectiveness and Duration of Protection of a Fourth Dose of COVID-19
mRNA Vaccine am and and delta variant waves. 2022.08.25.22278443 (2022).

Grewal, R. *et al.* Effectiveness and Duration of Protection of

mRNA Vaccine among Long-Term Care Residents in Ontario

(2022) doi:10.1093/infdis/jiac468.

Andrews Grewal, R. *et al.* Effectiveness and Duration of Protection
mRNA Vaccine among Long-Term Care Residents in Ont
(2022) doi:10.1093/infdis/jiac468.
Andrews, N. *et al.* Duration of Protection against Mild a
Vaccines. N. *En* 11. Grewal, n. et al. Effectiveness and Duration of Protection of a Fourth Dose of COVID-15
mRNA Vaccine among Long-Term Care Residents in Ontario, Canada. J. Infect. Dis. jiac46
(2022) doi:10.1093/infdis/jiac468.
12. Andr
- mark vaccine among Long-Term Care Residents in Ontario, Canada. J. Inject. Dis. jiac468.
(2022) doi:10.1093/infdis/jiac468.
Andrews, N. *et al.* Duration of Protection against Mild and Severe Disease by Covid-19
Vaccines. Andrews, N. *et al*. Duration of Prot
Vaccines. *N. Engl. J. Med.* **386**, 340
Milne, G. *et al.* Does infection with
immunity? *Lancet Respir. Med.* **9**, 1
CDC. *Rates of COVID-19 Cases and*
https://covid.cdc.gov/covid-dat
- 12. Andrews, N. et al. Daration of Protection against Mild and Severe Disease by Covid-15
Vaccines. N. Engl. J. Med. 386, 340–350 (2022).
13. Milne, G. et al. Does infection with or vaccination against SARS-CoV-2 lead to l
-
- Vaccines. *N. Liigi. 3. Med.* 386, 340–350 (2022).
Milne, G. *et al.* Does infection with or vaccinatio
immunity? *Lancet Respir. Med.* 9, 1450–1466 (2
CDC. *Rates of COVID-19 Cases and Deaths by Va*
https://covid.cdc.gov/ 13. Millie, G. et al. Does infection with or vaccination against SARS-COV-2 lead to lasting

immunity? Lancet Respir. Med. 9, 1450–1466 (2021).

14. CDC. Rates of COVID-19 Cases and Deaths by Vaccination Status.

https://c Immunity: Lancet Respir. Med. 3, 1430–1460 (2021).
CDC. *Rates of COVID-19 Cases and Deaths by Vaccina*:
https://covid.cdc.gov/covid-data-tracker (2022).
Andrews, N. *et al.* Covid-19 Vaccine Effectiveness aga
N. *Engl. J.* 14. CDC. *Rates of COVID-19 Cases and Deaths by Vaccination Status.*
https://covid.cdc.gov/covid-data-tracker (2022).
15. Andrews, N. *et al.* Covid-19 Vaccine Effectiveness against the Om
N. *Engl. J. Med.* **386**, 1532–15 Andrews, N. *et al.* Covid-19 Vaccine Effectiveness
N. Engl. J. Med. **386**, 1532–1546 (2022).
Hall, V. *et al.* Protection against SARS-CoV-2 after
Infection. *N. Engl. J. Med.* **386**, 1207–1220 (2022)
- 15. Andrews, N. et al. Covid-19 Vaccine Encetiveness against the Omicron (B.1.1.529) Variant.

16. Hall, V. *et al.* Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous

Infection. N. Engl. J. Med. 386, 1 N. Engl. J. Med. 386, 1552–1546 (2022).
Hall, V. *et al.* Protection against SARS-Co
Infection. *N. Engl. J. Med.* 386, 1207–122 16. Hall, V. et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous
Infection. N. Engl. J. Med. 386, 1207–1220 (2022). $I = \frac{1}{200}$. N. Engl. J. Med. 386, 1207–1220 (2022).
-
- 17. The United States of Susceptible People in Postmarketing Evaluations of COVID-19
18. Edlefsen, P. T. Leaky Vaccines Protect Highly Exposed Recipients at a Lower Rate:
18. Edlefsen, P. T. Leaky Vaccines Protect Highly E Vaccines. Am. J. Epidemiol. 191, 800–811 (2022).
Edlefsen, P. T. Leaky Vaccines Protect Highly Exposed Recipients at a Lower Rate:
Implications for Vaccine Efficacy Estimation and Sieve Analysis. Comput. Math. Method
Med. Vaccines. Am. J. Epidemiol. 191, 800–811 (2022).
Edlefsen, P. T. Leaky Vaccines Protect Highly Expo
Implications for Vaccine Efficacy Estimation and S
Med. 2014, e813789 (2014).
Langwig, K. E. et al. Limited available evid 18. Implications for Vaccine Efficacy Estimation and Sieve Analysis. Comput. Math. M.
19. Langwig, K. E. et al. Limited available evidence supports theoretical predictions of
19. Langwig, K. E. et al. Limited available evi
-
- Med. 2014, e813789 (2014).

Langwig, K. E. *et al.* Limited available evidence supports theoretical predictions of reduce

vaccine efficacy at higher exposure dose. *Sci. Rep.* 9, 3203 (2019).

Smith, P. G., Rodrigues, L. Med. 2014, e813789 (2014).
Langwig, K. E. *et al.* Limited a
vaccine efficacy at higher exp
Smith, P. G., Rodrigues, L. C.
against common diseases usi
(1984).
White, M. T., Griffin, J. T., Dra 19. Langwig, K. E. et al. Limited available evidence supports theoretical predictions of reduced
19. Vaccine efficacy at higher exposure dose. Sci. Rep. 9, 3203 (2019).
19. Smith, P. G., Rodrigues, L. C. & Fine, P. E. Asse
- Vaccine efficacy at higher exposure dose. Sci. Rep. 9, 3203 (2015).
Smith, P. G., Rodrigues, L. C. & Fine, P. E. Assessment of the protection
against common diseases using case-control and cohort studies. Interpretation.
(21. White, M. T., Griffin, J. T., Drakeley, C. J. & Ghani, A. C. Heterogeneity in malaria exposure
21. White, M. T., Griffin, J. T., Drakeley, C. J. & Ghani, A. C. Heterogeneity in malaria exposure
21. White, M. T., Griffi (1984).
(1984).
White, M. T., Griffin, J. T., Drakeley, C. J. & Ghani, A. C. Heterogeneity in malaria exposure
and vaccine response: implications for the interpretation of vaccine efficacy trials. *Malar. J.*
9, 82 (2010). (2084).
White, l
and vac
9, 82 (2
Read, A
Pathoge
Connec 21. Read, A. F. et al. Imperfect Vaccination Can Enhance the Transmission of Highly Virulent
22. Read, A. F. et al. Imperfect Vaccination Can Enhance the Transmission of Highly Virulent
23. Connecticut Department of Correc
-
- and vaccine response: implications for the interpretation of vaccine efficacy trials. Malar. J.
9, 82 (2010).
Read, A. F. *et al.* Imperfect Vaccination Can Enhance the Transmission of Highly Virulent
Pathogens. *PLOS Biol* 9, 92 (2020).
Read, A. F. *et*
Pathogens. *P.*
Connecticut I
Connecticut I
Count/tghy-y 22. Read, A. F. et al. Imperiet Vaccination Can Enhance the Transmission of Highly Virulent

Pathogens. PLOS Biol. 13, e1002198 (2015).

23. Connecticut Department of Correction. Correctional Facility Daily Population Coun Pathogens. PLOS Biol. 13, e1002198 (2019).
Connecticut Department of Correction. Corr
Connecticut Data. https://data.ct.gov/Public
Count/tghy-ygnr (2023).
Grubaugh, N. D. & Pham, K. *Yale SARS-CoV-2*
https://kphamyale.shin 23. Connecticut Data. https://data.ct.gov/Public-Safety/Correctional-Facility-Daily-Popula
24. Grubaugh, N. D. & Pham, K. Yale SARS-CoV-2 Genomic Surveillance Initiative.
24. Grubaugh, N. D. & Pham, K. Yale SARS-CoV-2 Geno
- Grubaugh, N. D. & Pham,
https://kphamyale.shiny. 24. Grubaugh, N. D. & Pham, K. Yale SARS-Cov-2 Genomic Surveillance Initiative.
https://kphamyale.shinyapps.io/covidtrackerct/ (2022). https://kphamyale.shinyapps.io/covidtrackerct/ (2022).
- 25. CDC. Potential Rippid Increase of Omicion Variant Infections in the Onice States.

https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/mathematical

outbreak.html (2021).

26. Bálint, G., Vörös-Horváth, B. &
-
- Bálint, G., Vörös-Horvá
decreased pathogenici
Mohsin, M. & Mahmud
transmissibility, immur
e29165 (2022). decreased pathogenicity. Signal Transduct. Target. Ther. 7, 1–3 (2022).
27. Mohsin, M. & Mahmud, S. Omicron SARS-CoV-2 variant of concern: A review on its
transmissibility, immune evasion, reinfection, and severity. Medici
- decreased pathogenicity. Signal Transduct: Target. Ther. 7, 1–3 (2022).
Mohsin, M. & Mahmud, S. Omicron SARS-CoV-2 variant of concern: A re
transmissibility, immune evasion, reinfection, and severity. *Medicine (B*
e29165 27. Moham, M. Annahmad, S. C. Mahmud, M. Andrew Coverity. Medicine (Baltimore) 10
28. Cerqueira-Silva, T. et al. Influence of age on the effectiveness and duration of prote
28. Cerqueira-Silva, T. et al. Influence of age o transmissibility, immune evasion, refinection, and severity. Medicine (Baltimore) 101,
e29165 (2022).
Cerqueira-Silva, T. *et al.* Influence of age on the effectiveness and duration of protection
Vaxzevria and CoronaVac va
- Cerqueira-Silva,
Cerqueira-Silva,
Vaxzevria and C
(2022).
Ranzani, O. T. *ei*
variant associat 28. Cerqueira-Silva, T. et al. Influence of age on the effectiveness and duration of procedum of
Vaxzevria and CoronaVac vaccines: A population-based study. *Lancet Reg. Health – Am.* 6,
29. Ranzani, O. T. *et al.* Effecti Vaxzevria and Coronavac vaccines. A population-based study. *Lancet Reg. Ticum – Am.* 6,
(2022).
Ranzani, O. T. *et al.* Effectiveness of the CoronaVac vaccine in older adults during a gamma
variant associated epidemic of (2022).
Ranzani
variant
n2015 (
Powell,
Infect. L 29. Ranzani, O. T. et al. Effectiveness of the Coronavac vaccine in older adults during a gamma
variant associated epidemic of covid-19 in Brazil: test negative case-control study. *BMJ* 374
n2015 (2021).
30. Powell, A. A.
-
- variant associated epidemic of covid-19 in Brazil: test negative case control study. BMJ 374,
n2015 (2021).
Powell, A. A. *et al.* Effectiveness of BNT162b2 against COVID-19 in adolescents. *Lancet*
Infect. Dis. 22, 581–58
- n2022 (2022).
Powell, A. A. et
Infect. Dis. 22,
Han, S. et al. Ti
limited vaccina
Halloran, M. E.
(Springer, 2010 30. Power, A. A. et al. Enectiveness of BNT162b2 against COVID-19 in adolescents. Lancet

Infect. Dis. 22, 581–583 (2022).

31. Han, S. et al. Time-varying optimization of COVID-19 vaccine prioritization in the conte:

lim Infect. Dis. 22, 581–583 (2022).
Han, S. *et al*. Time-varying optin
limited vaccination capacity. Na
Halloran, M. E., Longini, I. M. &
(Springer, 2010). doi:10.1007/9
Lewnard, J. A., Tedijanto, C., Co[.]
Effects Under the 31. Han, S. et al. Time-varying optimization of COVID-19 vaccine prioritization in the context of

limited vaccination capacity. *Nat. Commun.* **12**, 4673 (2021).

32. Halloran, M. E., Longini, I. M. & Struchiner, C. J. *D* Inince vaccination capacity. Nat. Commun. 12, 4673 (2021).
Halloran, M. E., Longini, I. M. & Struchiner, C. J. *Design and A.*
(Springer, 2010). doi:10.1007/978-0-387-68636-3.
Lewnard, J. A., Tedijanto, C., Cowling, B. J.
- 32. Halloran, M. E., Longini, I. M. & Struchlier, C. J. Design and Analysis of Vuccine Stadies.

(Springer, 2010). doi:10.1007/978-0-387-68636-3.

33. Lewnard, J. A., Tedijanto, C., Cowling, B. J. & Lipsitch, M. Measuremen Lewnard, J. A., Tedijanto, C., Cowling, B. J. & Lipsitc
Effects Under the Test-Negative Design. Am. J. Epic
The Test-Negative Design. Am. J. Epic Effects Under the Test-Negative Design. Am. J. Epidemiol. 187, 2686–2697 (2018). Effects Under the Test-Negative Design. Am. J. Epidemiol. 187, 2000–2007 (2018).

-
-
- 35. Brooks-Pollock, E. et al. High COVID-19 transmission potential associated with re-opening
35. Brooks-Pollock, E. et al. High COVID-19 transmission potential associated with re-opening
36. Zhang, Y., Mayorga, M. E., Ivy Brooks-Pollock, E. *et al.* High COVID-19 transmission potential associated with re-opening
universities can be mitigated with layered interventions. *Nat. Commun.* 12, 5017 (2021).
Zhang, Y., Mayorga, M. E., Ivy, J., Hass 35. Brooks-Pollock, E. et al. High COVID-19 transmission potential associated with the opening

universities can be mitigated with layered interventions. *Nat. Commun.* 12, 5017 (2021).

36. Zhang, Y., Mayorga, M. E., Ivy, 2017 (2021).
2018, Y., Mayorga, M. E., Ivy, J., Hassmiller Lich, K. & Swann, J. L. Modeling the Impact of
2018 Nonpharmaceutical Interventions on COVID-19 Transmission in K-12 Schools. MDM Polic.
2018 Nonpharmaceutical Int 36. 2012. Nonpharmaceutical Interventions on COVID-19 Transmission in K-12 Schools. MDM Policy

Pract. 7, 23814683221140864 (2022).

37. Bowen, J. E. *et al.* Omicron spike function and neutralizing activity elicited by a

-
- Nonpharmaceutical Interventions on COVID-19 Transmission in K-12 Schools. MDM Policy
Pract. 7, 23814683221140864 (2022).
Bowen, J. E. *et al.* Omicron spike function and neutralizing activity elicited by a
comprehensive pa Pract. 7, 23814683221146864 (2022).
Bowen, J. E. *et al*. Omicron spike functi
comprehensive panel of vaccines. *Scie.*
Accorsi, E. K. *et al*. Association Betwee
Symptomatic Infection Caused by the :
doi:10.1001/jama.2022 37. Bowen, J. E. et al. Omicron spike function and neutralizing activity encriced by a
comprehensive panel of vaccines. Science 377, 890–894 (2022).
38. Accorsi, E. K. *et al.* Association Between 3 Doses of mRNA COVID-19 comprenensive panel of vaccines. Science 377, 890–894 (2022).
Accorsi, E. K. *et al.* Association Between 3 Doses of mRNA COVID
Symptomatic Infection Caused by the SARS-CoV-2 Omicron and
doi:10.1001/jama.2022.0470.
Chen, J 39. Accorsi, E. K. et al. Association Between 3 Boses of mixine COVID-13 vaceline and
39. Chen, J., Wang, R., Gilby, N. B. & Wei, G.-W. Omicron Variant (B.1.1.529): Infectiv
39. Chen, J., Wang, R., Gilby, N. B. & Wei, G.-W
-
- Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. SAMA (2022)
doi:10.1001/jama.2022.0470.
Chen, J., Wang, R., Gilby, N. B. & Wei, G.-W. Omicron Variant (B.1.1.529): Infectivity,
Vaccine Breakthroug Chen, J., Wang, R., Gilby, N. B.
Vaccine Breakthrough, and An
Bobrovitz, N. *et al*. Protective
immunity against the omicron
regression. *Lancet Infect. Dis.* :
Chemaitelly, H. *et al*. Protectio Vaccine Breakthrough, and Antibody Resistance. J. Chem. Inf. Model. 62, 412–422 (20
40. Bobrovitz, N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hyl
immunity against the omicron variant and severe Vaccine Breakthrough, and Antibody Resistance. J. Chem. Inj. Model. 62, 412–422 (2022).
Bobrovitz, N. *et al.* Protective effectiveness of previous SARS-CoV-2 infection and hybrid
immunity against the omicron variant and s
- 40. Bobrovitz, N. et al. Protective encetiveness or previous SARS-CoV-2 infection and night
immunity against the omicron variant and severe disease: a systematic review and meta-
regression. *Lancet Infect. Dis.* 23, 556–5 regression. *Lancet Infect. Dis.* 23, 356–567 (2023).
Chemaitelly, H. *et al.* Protection from previous nat
vaccination against SARS-CoV-2 infection and seve
cohort study. *Lancet Microbe* **3**, e944–e955 (2022)
Murugesan, 41. Chematelly, H. et al. Protection from previous natural infection compared with mixing
vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective
cohort study. *Lancet Microbe* 3, e944–e955 (
- vacantistination against SARS-Constrained COV-2 in the COV-2 in Qatarita Cover-
cohort study. *Lancet Microbe* 3, e944–e955 (2022).
Murugesan, M. *et al.* Protective effect conferred by prior infection and vaccination on
C cohort study. *Lancet Microbe* 3, e944–e955 (2022).
Murugesan, M. *et al.* Protective effect conferred by
COVID-19 in a healthcare worker cohort in South Inc 42. Murugesan, M. et al. Protective effect conferred by prior infection and vaccination on
COVID-19 in a healthcare worker cohort in South India. *PLOS ONE* 17, e0268797 (2022) COVID-19 in a healthcare worker cohort in South India. PLOS ONE 17, e0268797 (2022).

-
- 43. Jones, J. M. et al. Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence
Estimates Based on Blood Donations, July 2020-December 2021. JAMA 328, 298-301
(2022).
44. Centers for Disease Control and Prevent Estimates Based on Blood Donations, July 2020 December 2021. JAMA 328, 258–301
(2022).
Centers for Disease Control and Prevention (CDC). 2020-2021 Nationwide Blood Dono
Seroprevalence Survey | Connecticut. https://covid19s (2022).
Centers
Seropre
873f-4b
Tan, S. ⁻
during t
Contact 44. Centers for Disease Control and Prevention (CDC). 2020-2021 Nationwide Blood Donor
Seroprevalence Survey | Connecticut. https://covid19serohub.nih.gov/studies/S-1f88de
873f-4b2a-8ec0-33041516e86c (2021).
45. Tan, S. T.
-
- Seroprevalence Survey | Connecticut: https://covid.153erohub.nih.gov/studies/S-1fioduced
873f-4b2a-8ec0-33041516e86c (2021).
Tan, S. T. *et al.* Infectiousness of SARS-CoV-2 breakthrough infections and reinfections
during Tan, S. T. *et al.* Infectiousness of SARS-C
during the Omicron wave. Nat. Med. 1–
Contact Tracing for COVID-19. *Centers f*
https://www.cdc.gov/coronavirus/2019
plan/contact-tracing.html (2022).
Poopalasingam, N. *et al.* 45. Tan, 5. T. et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections
during the Omicron wave. Nat. Med. 1–8 (2023) doi:10.1038/s41591-022-02138-x.
46. Contact Tracing for COVID-19. Centers for Diseas during the Omicron wave. Mat. Med. 1–6 (2023) doi:10.1038/s41391-022-02138-x.
Contact Tracing for COVID-19. *Centers for Disease Control and Prevention*
https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact 46. Contact Tracing for COVID-19. Centers for Disease Control and Prevention
https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contac
plan/contact-tracing.html (2022).
47. Poopalasingam, N. *et al.* Determining
-
- plan, 2006 a arring.html (2022).
Poopalasingam, N. *et al.* Determin
in fully vaccinated individuals. J. *C.*
Lind, M. L. *et al.* Testing Frequency
a Severe Acute Respiratory Syndre
Correctional Facilities. *Clin. Infect.* 47. Poopalasingam, W. et al. Determining the reliability of rapid SARS-CoV-2 antigen detection
in fully vaccinated individuals. J. Clin. Virol. 148, 105119 (2022).
48. Lind, M. L. et al. Testing Frequency Matters: An Evalu
- in fully vacemated individuals. J. Cliff. Virol. 148, 105115 (2022).
Lind, M. L. *et al.* Testing Frequency Matters: An Evaluation of the
a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
Correctional Facilities 48. Lind, M. L. et al. Testing Frequency Matters: An Evaluation of the Diagnostic Feriorinance of
a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Rapid Antigen Test in US
Correctional Facilities. *Clin. Infe* Correctional Facilities. *Clin. Infect. Dis.* ciac450 (2022) doi:10.1093/cid/ciac450.
Connecticut Department of Correction. Health Information and Advisories. *CT.gov -*
Connecticut's Official State Website https://portal. Connectional Facilities. C*lin. Infect. Dis.* ciac450 (2022) doi:10.10937cM7clac450.
Connecticut's Official State Website https://portal.ct.gov/DOC/Common-
Elements/Common-Elements/Health-Information-and-Advisories (2023).
- 49. Connecticut's Official State Website https://portal.ct.gov/DOC/Common-
Elements/Common-Elements/Health-Information-and-Advisories (2023).
50. Lind, M. L. et al. Covid-19 Vaccine Acceptance Among People Incarcerated in Elements/Common-Elements/Health-Information-and-Advisories (2023).
Elements/Common-Elements/Health-Information-and-Advisories (2023).
Lind, M. L. *et al.* Covid-19 Vaccine Acceptance Among People Incarcerate
State Jails. 2 Elind, M. L. *et al.* Covid-19 Vaccine Acceptance Among People Incarcerated
State Jails. 2022.05.19.22275339 Preprint at https://doi.org/10.1101/202
(2022). 50. Lind, M. L. et al. Covid-15 vaccine Acceptance Among People Incarcerated in Connecticut
State Jails. 2022.05.19.22275339 Preprint at https://doi.org/10.1101/2022.05.19.2227533
(2022). (2022).
222.
22 (202)

Infection in an Incarcerated Population. (2023) doi:600233692.

The Leaky Protection Following COVID-19 Vacanties Cover-20 Vacanties Cover-20 Vacanties Cover-20 Vacanties Cover-20 Vacanties Cover-20 Vacanties Cover-20 Vaca Infection in an Incarcerated Population. (2023) doi:600233692.

Acknowledgements: We are grateful to the individuals who provided the information for the analyses and thank the staff of the Connecticut Department of Corrections for their efforts in the response to the COVID-19 pandemic and in collecting data for the study. We also thank Ryan Borg and Dava Flowers-Poole for their assistance in the coordination of the study. This work was supported by a contract from the Connecticut Department of Public Health (Emerging Infections Program 2021-0071 to A.I.K.), the Raj and Indra Nooyi Professorship (to A.I.K), and the Merck Investigator Studies Program (to W.L.S. and A.I.K.). The funders did not have a role in the design or implementation of the study nor the decision to publish the study. The study and its findings are the responsibility of the authors and do not reflect the views of the Connecticut Department of Correction.

Author Contributions Statement: MLL and AIK have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. MLL, AIK, RPR, and BSK conceived the study. The data was collected and processed by MLL, MD, AJH, ML, BSK, and RPR. MLL, MD, MDTH, DATC, RT, and SL performed the analysis. MLL, AIK, BSK, MDTH, DATC, JRA, IY, SBO, WLS, and RR drafted the manuscript. All authors provided critical review of the results and contributed to manuscript revision. AJH, ML, BSK, RPR, and AIK supplied administrative, technical, and material support. Supervision was provided by BSK, RPR, DATC, and AIK.

Ethics declarations:

Competing Interests Statement

A.I.K is as an expert panel member for Reckitt Global Hygiene Institute, and a consultant for Tata Medical and Diagnostics and Regeneron Pharmaceuticals and has received grants related to COVID-19 research outside the scope of the proposed work from Regeneron Pharmaceuticals and Tata Medical and Diagnostics. W.L.S. was an investigator for a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; is a technical consultant to Hugo Health, a personal health information platform, and co-founder of Refactor Health, an AI-augmented data management platform for healthcare; and has received grants related to COVID-19 research outside the scope of the proposed work from Regeneron Pharmaceutical. Other authors declare no conflict of interest.

Tables

Table 1: Characteristics of Residents with and without Documented Exposure to SARS-CoV-2 Infected Residents

^a Duration of incarceration (in days) including the SARS-CoV-2 exposure event type by the base of the base of the base by the base of t

^b Number of cellmates or unit-mates at the time of the exposure event that resulted in study inclusion

 \textdegree History of prior infection defined as a record of prior infection (defined as prior infection defined as the record of a positive SARS-CoV-2 test (rapid antigen or RT-PCR) recorded prior infection and vaccination as of the start of the study period

Figure Legends

Figure 1: Vaccination coverage, SARS-CoV-2 testing, Proportion of Residents Tested, and SARS-CoV-2 infections in the Connecticut Correctional Facility system between June 15, 2021, and May 10, 2022

The (A) vaccination coverage (red: boosted, light blue: primary vaccination, green: partially vaccinated, navy: unvaccinated), (B) number of SARS-CoV-2 tests conducted as part of mass screening (light blue), contact tracing in the absence of recorded symptoms (navy), intake/transfer testing in the absence of recorded symptoms (grey/blue), other testing in the absence of recorded symptoms (brown), and testing in the presence of recorded symptoms (symptoms data not available for mass screening [PCR] testing; red), (C) proportion of residents tested during a rolling 14-day period among all residents (red) and residents with cell exposure events (green), cellblock exposure events (brown), and no documented exposure events (navy), (D) number of SARS-CoV-2 infections detected as part of mass screening (light blue), contact tracing in the absence of recorded symptoms (navy), intake/transfer testing in the absence of recorded symptoms (grey/blue), other testing in the absence of recorded symptoms (brown), and testing in the presence of recorded symptoms (red) among people who resided in Connecticut Department of Correction Facility cells between June 15, 2021, and May 10, 2022. During the study period, RT-PCR tests were collected for mass testing and rapid antigen tests were collected for the following primary reasons: intakes/transfer, contact tracing, symptom presence, and employment. Infections were defined as a positive test (RT-PCR or rapid antigen test) collected in the absence of a positive test in the last 90 days. Residents were classified as having a cell exposure event on the day their cellmate tested positive, having a cellblock exposure event the day a resident of their cellblock but not cell tested positive, and having an event without documented exposures if no one in their cellblock tested positive on a given day.

Figure 2: Selection of the rolling matched cohort of residents according to their facility exposures

Flowchart showing how people incarcerated within Connecticut Department of Correction facilities and who resided in cells between June 15, 2021, and December 12, 2021 (Delta Predominant Period [A]) and December 13, 2021, and May 10, 2022 (Omicron Predominant Period [B]), were included in the analysis. Residents were classified as having a cell exposure event (green) on the day their cellmate tested positive, having a cellblock exposure event (brown) the day a resident of their cellblock but not cell tested positive, and having an event without documented exposure (navy) if no one in their cellblock tested positive on a given day. Cell exposure events that occurred within 14 days following a prior cell exposure event were excluded. Cellblock exposure events and events without documented exposures that occurred in the 14 days following a cellblock or cell exposure event were excluded. ^aTo prevent the inclusion of multiple events without documented exposures from the same person during a 14 day period, we randomly selected incarceration events without documented exposures and excluded all others within the prior or following 14 days. ^bWe defined infections as a positive RT-PCR or rapid antigen test during the 14 days of follow-up.

Figure 3: Association between documented exposure and SARS-CoV-2 infection risk among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022

Forest plot depicting the association between documented close exposure to a SARS-CoV-2 infected resident and the risk of subsequent SARS-CoV-2 infection. Residents were classified as having a cell exposure event (green) on the day their cellmate tested positive, having a cellblock exposure event (brown) the day a resident of their cellblock but not cell tested positive, and having an event without documented exposure if no one in their cellblock tested positive on a given day. Cell exposure events that occurred within 14 days following a prior cell exposure event were excluded. Cellblock exposure events and events without documented exposures that occurred in the 14 days following a cellblock or cell exposure event were excluded. Facility exposures were stratified by periods of variant predominance (Delta [A]: June 15, 2021 – December 12, 2021; Omicron [B]: December 13, 2021 – May 10, 2022). The associations were estimated using a Cox Proportional Hazard Model stratified by facility and with robust standard errors. The model was adjusted for age, calendar date, race, room and cellblock size, vaccination, and prior infection status of the susceptible person. Boxes indicate estimated hazard ratio (HR) point values and whiskers indicate 95% confidence intervals (Delta Period: n $= 22,904$ facility events; Omicron Period: $n = 20,146$ facility events). Unadjusted results presented in Supplement Table 3.

Figure 4: Effectiveness of prior infection vaccination, and hybrid immunity on SARS-CoV-2 infection among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022, by documented exposure status

Forest plot depicting the association between prior infection, vaccination, and hybrid immunity and the risk of SARS-CoV-2 infection by facility exposure type. Residents were classified as having a cell exposure event (green) the day their cellmate tested positive, having a cellblock exposure event (brown) the day a resident of their cellblock but not cell tested positive, and having an event without documented exposure (navy) if no one in their cellblock tested positive. Cell exposure events that occurred within 14 days following a prior cell exposure event were excluded. Cellblock exposure events and events without documented exposure that occurred in the 14 days following a cellblock or cell exposure event were excluded. Associations were examined using Cox Proportional Hazard Models stratified by cellblock with robust standard errors. Each model was adjusted for age, date of exposure, race, room size, and model (a) was adjusted for vaccination status and model (b) was adjusted for prior infection status. Model (c) was limited to residents with hybrid immunity or residents without a record of prior infection or vaccination. Prior infection was defined as a recorded positive SARS-CoV-2 test ≥90 days
before the event and vaccination was defined as the receipt of ≥1 dose before the event. Hybrid immunity was defined as a record of both a prior infection and ≥ 1 vaccine dose. Boxes indicate immunity was defined as a record of both a prior infection and ≥1 vaccine dose. Boxes indicate estimated hazard ratio (HR) point values and whiskers indicate 95% confidence intervals (Delta: n = 17,024 no exposure events, 5,616 cellblock exposure events, 264 cell exposure events; Omicron: n = 13,464 no exposure events, 5,980 cellblock exposure events, 702 cell exposure events). Ratio of HRs refer to the p-value comparing the HR following cellblock or cell exposure events to the HR following events without documented exposures, estimated using two-sided ztests. No multiple testing adjustment was performed. Unadjusted results in Supplement Table 7.

Figure 5: Effectiveness of prior infection and vaccination status of index cases on SARS-CoV-2 transmissibility among of residents of Connecticut Department of Correction facility between June 15, 2021, and May 10, 2022, by documented SARS-CoV-2 exposure status

Forest plot depicting the association between vaccination and prior infection and the risk of subsequent SARS-CoV-2 infection by documented SARS-CoV-2 exposure status. Residents were classified as having a cell exposure event (green) on the day their cellmate tested positive, having a cellblock exposure event (brown) the day a resident of their cellblock but not cell tested positive, and having an event without documented exposure if no one in their cellblock tested positive on a given day. Cell exposure events that occurred within 14 days following a prior cell

exposure event were excluded. Cellblock exposure events and events without documented exposures that occurred in the 14 days following a cellblock or cell exposure event were excluded. Residents were classified as being vaccinated if they had received at least one vaccine dose. Associations were examined using Cox Proportional Hazard Models stratified by housing cellblock with robust standard errors. The models were adjusted for (a) age, date of exposure, race, room size, vaccination and prior infection status of the susceptible resident, and vaccinated status of the index case (limited to exposed residents), (b) age, date of exposure, race, room size, vaccination and prior infection status of the susceptible resident, and prior infection status of the index case (limited to exposed residents). Prior infections were defined as a recorded positive SARS-CoV-2 test at least 90 days prior to the event and vaccination was defined as the receipt of at least one dose prior to the event. Boxes indicate estimated hazard ratio (HR) point values and whiskers indicate $95%$ confidence intervals (Delta: $n = 4,407$ cellblock exposure events, 127 cell exposure events; Omicron: n = 3,831 cellblock exposure events, 250 cell exposure events).

Figures

Figure 1: *Vaccination coverage, SARS-CoV-2 testing, Proportion of Residents Tested, and SARS-CoV-2 infections in the Connecticut Correctional Facility system between June 15, 2021, and May 10, 2022*

Figure 2: *Selection of the rolling matched cohort of residents according to their facility exposures*

Figure 3: *Association between documented exposure and SARS-CoV-2 infection risk among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022*

A. Delta Period

Figure 4: *Effectiveness of prior infection vaccination, and hybrid immunity on SARS-CoV-2 infection among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022, by documented exposure status*

Figure 5: *Effectiveness of prior infection and vaccination status of index cases on SARS-CoV-2 transmissibility among of residents of Connecticut Department of Correction facility between June 15, 2021, and May 10, 2022, by documented SARS-CoV-2 exposure status*

